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Abstract  
Babesia species, etiological agents of babesiosis, a recognized emerging vector-borne 
zoonose, are a significant animal and human health concern with a worldwide socio-economic 
impact.  Genetic manipulation methods are pivotal to improve knowledge regarding the biology 
of these poorly studied parasites towards better disease control strategies. For Babesia ovis, 
responsible for ovine babesiosis, a tick-borne disease of small ruminants, these tools are not yet 
available.  
Transfection technologies have a wide range of applications, being particularly useful 
in the study of the parasite-host cell interactions. The establishment of parasites expressing a 
fluorescent marker has allowed imaging of tick vector colonization, an approach that can also 
be applied to clarify B. ovis and related Babesia spp. life cycle events in the tick vector tissues. 
Thus, the main goal of this study was to set up basis for the development of a stable transfection 
system, driving expression of a fluorescent marker for B. ovis.  
The present work has four objectives, (1) screening of regulatory regions in B. ovis 
genome and/or identification of heterologous promoters from other Babesia species, (2) 
development of transient transfection systems with the previously selected regions and 
evaluation of transfection conditions, promoter activity, transfection efficiency, (3) 
identification of a proper selection system for upcoming stable transfection of B. ovis and (4) 
the development of the plasmid construct for B. ovis stable transfection. 
The study was based on the existence of interchangeable cross-species functional 
promoters between Babesia species. Therefore, first steps consisted in the development of 
transient transfection constructs with elongation factor 1-alpha (ef-1α) promoter regions from 
B. bovis and B. ovata to drive expression of the luciferase reporter gene. A promoterless plasmid 
was also developed to use as negative control in the luminescence assays.  
Herein, we describe for the first time B. ovis transient transfection using heterologous 
promoters, the ef-1α-B intergenic regions from B. bovis and B. ovata. Their ability to drive 
expression of a reporter luciferase in B. ovis supports their cross-species functionality. The ef-
1α-B promoter region from B. ovata resulted in the expression of high luciferase levels, thus an 
appropriate promoter for stable gene expression. Transfection efficiency was evaluated through 
qPCR to preclude the hypothesis that higher luminescence values were related with a higher 
transfection efficiency.  
Based on available sequences from B. bovis, B. bigemina and B. divergens, PCR 
experiments were performed aiming the search for regulatory elements in B. ovis genome. 
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Analysis of the actin 5’ flanking region revealed homology with B. bovis actin promoter but 
curiously the absence of a transcriptional start site consensus motif common between B. bovis 
and Theileria species. Regarding ef-1α and rhoptry associated protein -1 (rap-1) locus, their 
organization in B. ovis remains unclear but it was possible to retrieve a rap-1 intergenic region 
with transcription termination signals, essential for the development of future autologous 
transfection systems. Also, a potential region for stable construct integration has been 
sequenced, the ef-1α gene.  
Evaluation of B. ovis sensitivity to WR99210 and blasticidin-S, antibiotics commonly 
used to select apicomplexan transfectants, has been performed and blasticidin-S was identified 
as a selectable marker for future stably transfected B. ovis.  
Currently, efforts are being conducted in the construction of a stable transfection 
plasmid with the ef-1α-B promoter region from B. ovata driving expression of a fluorescent 
reporter gene and an antibiotic resistance gene. The establishment of a B. ovis lineage 
expressing a fluorescent reporter gene will be applied to study B. ovis life cycle, enlightening 
interactions with the host cells.  
 
Keywords: Babesia ovis, transient transfection, elongation factor-1alpha, plasmid 
construction, luciferase, sensitivity assays 
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Resumo  
Os parasitas do género Babesia são agentes etiológicos de babesiose, uma zoonose 
emergente transmitida por carraças, reconhecida com uma ameaça importante para a saúde 
animal e humana e com um impacto socioeconómico a nível mundial. Métodos de manipulação 
genética são essenciais para o conhecimento da biologia destes pouco estudados organismos, 
de forma a melhorar as estratégias para o seu controlo. Em Babesia ovis, agente responsável 
pela babesiose ovina, tais metodologias não foram, até à data, desenvolvidas.   
A transfecção é uma metodologia que têm inúmeras aplicações, sendo particularmente 
útil no estudo de interações parasita-célula hospedeira. O estabelecimento de uma linhagem de 
parasitas a expressar um marcador fluorescente permitiu monitorizar a colonização do vector 
pelo agente patogénico. Esta estratégia pode ser também aplicada para clarificar eventos do 
ciclo de vida de B. ovis e de outras espécies do género Babesia, na carraça vector. Desta forma, 
o principal objetivo do presente estudo foi o de criar os pilares necessários ao desenvolvimento 
de um sistema para transfecção estável capaz de expressar um marcador fluorescente em B. 
ovis.  
O presente trabalho apresenta quatro objetivos, (1) o screening de regiões reguladoras 
no genoma de B. ovis e/ou a identificação de promotores heterólogos noutras espécies do género 
Babesia, (2) o desenvolvimento de sistemas para transfecção transiente com as regiões 
reguladoras previamente selecionadas bem como a avaliação de parâmetros da transfecção, 
atividade das regiões promotoras e eficiência da transfecção, (3) identificação de um sistema 
de seleção apropriado para isolar B. ovis transfectada de forma estável e (4) o desenvolvimento 
de um plasmídeo para transfecção estável de B. ovis.  
Este estudo baseou-se na existência de promotores funcionais e intercambiáveis entre 
espécies do género Babesia. Sendo assim, o trabalho iniciou com o desenvolvimento de 
plasmídeos para transfecção transiente contendo uma das regiões promotoras do factor de 
elongação-1alfa (ef-1α) de B. bovis e B. ovata permitindo a expressão do gene repórter que 
codifica para a luciferase.  
O presente trabalho descreve, pela primeira vez, a transfecção transiente de B. ovis, 
sendo que ambas as regiões promotoras utilizadas permitiram a expressão da luciferase em B. 
ovis corroborando a sua funcionalidade entre espécies. Em particular a região promotora de B. 
ovata induziu a expressão de níveis elevados de luciferase, revelando ser uma região promotora 
adequada para incorporar num sistema que permita uma transfecção estável. A eficiência de 
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transfecção foi avaliada através de análise por qPCR de forma a validar que as diferenças 
observadas nos valores de luminescência não estavam relacionadas com diferenças na 
eficiência do processo de transfecção. 
Tendo por base sequências de B. bovis, B. bigemina e B. divergens, foram realizados 
PCR com objetivo de amplificar regiões reguladoras no genoma de B. ovis. Análise da região 
5’ flanqueante da actina revelou homologia com a região promotora da actina em B. bovis, 
embora, curiosamente, a sequência consenso em B. bovis e espécies do género Theileria para 
iniciação da transcrição estivesse ausente. Relativamente ao locus do ef-1α e da rhoptry 
associated protein -1 (rap-1), a sua organização ainda não está esclarecida tendo sido possível 
obter a região intergénica de rap-1. Esta região apresenta sinais de terminação podendo ser 
utilizada para um futuro sistema para transfecção constituído por regiões reguladoras autólogas. 
Foi ainda sequenciada uma possível região para integração de um construto estável no genoma 
de B. ovis, o gene ef-1α.  
A blasticidina-S foi selecionada como agente selector de B.ovis transfectados após 
ensaios de suscetibilidade aos antibióticos WR99210 e blasticidina-S, comummente utilizados 
para selecionar espécies transfectada do filo apicomplexa. 
O desenvolvimento de um plasmídeo para transfecção estável está em curso o que 
permitirá estabelecer uma linhagem de B. ovis a expressar a proteína fluorescente vermelha 
(RFP). Os resultados do presente trabalho decerto irão contribuir para melhor compreender o 
parasita bem como interações com células hospedeiras.  
 
Palavras-chave: Babesia ovis, transfecção transiente, factor de elongação-1alpha, construção 
de plasmídeos, luciferase, ensaios de suscetibilidade 
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1. Introduction 
Development of genetic manipulation methods for Babesia ovis can provide an essential 
breakthrough for the study of this parasite basic biology, including its life cycle dynamics, 
parasite-vector and parasite-host interactions, ultimately enabling rational design of more 
effective drugs and vaccines towards disease control 1,2. 
 Currently, scarce information regarding intra-tick Babesia species (spp.) dynamics 
exists, even though targeting key developmental stages in tick tissues presents as an attractive 
way towards the development of transmission-blocking vaccines. Such approach demands a 
deep knowledge of conserved and divergent developmental features between Babesia spp. 3. 
Transfection technology (incorporation and expression of foreign DNA or RNA) has a 
wide range of applications, particularly useful for the study of parasite-host cell interactions. 
Recently, it was possible to image pathogen colonization in its tick vector by transforming the 
bacteria Borrelia sp. to stably express a fluorescent marker, thus the same strategy could be 
applied to understand B. ovis and related Babesia spp. life cycle events in the tick vector tissues 
4. Even though there is very limited knowledge regarding B. ovis-Rhipicephalus bursa 
interactome, some candidate protective antigens have been identified recently in the tick vector 
salivary glands, as having an important role in biological functions, such as tick development, 
feeding and pathogen transmission 5. Transfection methods stand out also in the vaccinomics 
research currently ongoing for the B. ovis-R. bursa interface, by enabling targeted disruption of 
genes of interest leading to the identification of key/essential parasite gene products for 
successful transmission 2,5–8. Moreover, the same gene manipulation strategy can be applied to 
the study of virulence factors, particularly those that interact with effectors produced by the 
host immune system. The phenotypic characterization of mutants lacking or with partially 
functional virulence factors can be a powerful method to characterize these factors, which can 
be potential targets for vaccine development 2,9. Other possible endpoint of this tool is the design 
of novel-life transfection-based vaccines, in which the host is vaccinated with attenuated-live 
vector vaccine containing a stably transfected tick antigen, eliciting the host protective immune 
response against both the parasite and the tick 10,11. 
Babesia spp. have many characteristic features that make this parasite especially 
suitable for the development of genetic manipulation methods and posterior identification of 
drug targets 12. A small genome size in comparison to other apicomplexan parasites simplifies 
comparative genomic studies and, the relatively reduced number of genes concomitantly with 
being haploid in the asexual cycle also facilitates the discovery of drug targets 13–15. Moreover, 
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it appears that the integration of exogenous DNA in Babesia spp. genome occurs exclusively 
by a homologous recombination mechanism which supports the development of gene knockout 
experiments for functional studies 8. Currents challenges for the development of such tools are 
related with scarce of appropriately annotated genomes and, particularly for B. ovis, the 
unavailability of its genome sequence in public databases 13,15–18.   
The “One Health” concept recognizes that Human, animal and environment Health are 
tightly intertwined, demanding synergistic interdisciplinary collaborations to, among other 
purposes, pave the way for the expansion of scientific knowledge. Research projects that aim 
the control of tick and tick-borne diseases have been positioned in the framework provided by 
this initiative, prioritizing the use of “omnics” and systems biology approaches concomitantly 
with the development of genetic manipulation methods 2,19.  
1.1. Babesia and Babesiosis   
The genus Babesia (phylum Apicomplexa, order Piroplasmida) comprises protozoan 
hemoparasites responsible for babesiosis, a recognized emerging vector-borne zoonose. More 
than one-hundred Babesia spp. have been identified so far, remarkably able to establish 
infections in a wide variety of domestic and wild animals, with some species having the ability 
to infect humans. These organisms are considered the second most prevalent blood-borne 
parasites of mammals after trypanosomes and, giving the worldwide distribution of their tick 
vectors, babesiosis is recognized as the most common blood disease of free living animals 20–
25. 
Babesia spp. were named after Victor Babes, the bacteriologist that provided their first 
description in 1888, after observation of these microorganisms inside erythrocytes of cattle 
presenting hemoglobinuria and later in sheep blood. In 1893, Smith and Kilbourne identified 
this intraerythrocytic parasite as the etiological cause of Texas Cattle Fever and also the role of 
ticks as vectors, being the firsts to demonstrate that an arthropod was the carrier of a disease 
agent 26–28. Indeed, transmission usually occurs through a Babesia-infected tick bite but it can 
also happen via blood transfusion or congenital acquisition during pregnancy 27.  
Babesiosis is acknowledged for having a great impact at economic and social levels, 
particularly in developing countries. In addition, the intensification of human and animal 
movements combined with environmental changes and the geographical expansion of several 
tick species is contributing to the rise of this tick-borne disease as a global threat 29–31.   
From the veterinary point of view, bovine babesiosis, caused by Babesia bovis and 
Babesia bigemina, has drawn more attention due to the economic burden imposed, linked to 
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mortalities, abortions, decreased milk and meat production, control measure costs, losses in 
potential production and cattle trade restrictions 21,32,33. Despite existence of tick vector 
eradication programs disease outbreaks occur often and it is considered that most of the 1.2 
billion cattle worldwide is exposed to babesiosis 34–36. Moreover, ovine babesiosis caused 
mainly by B. ovis has a major economic impact and companion animals, such as dogs, are also 
severely affected with infections caused by Babesia vogeli and Babesia gibsoni 21,37–40. 
From the medical point of view, human babesiosis, caused by an increasing diverse 
range of species, mainly attributed to Babesia microti and Babesia divergens, is still not 
recognized as a neglected disease 27,41–45. Even though humans are only considered accidental 
hosts for Babesia spp., there is a global concern regarding this emerging zoonosis since human 
babesiosis incidence is increasing with several clinical cases being reported recently from many 
countries worldwide, as reviewed by Yabsley and Shock., 2013 and Ord and Lobo, 2015 27,43. 
Moreover, babesial infections are often overlooked due to the relative unspecific clinical signs 
and lack of medical awareness for this disease, with underreporting of human cases being a 
major issue 45,46. 
Babesiosis clinical signs arise when the rate of erythrocyte (infected) loss surpasses the 
rate of their replacement, giving rise to anemia and its associated health issues. Therefore, 
babesial infections progress with quite different degrees of severity depending of hosts’ age, 
immunological status, co-infections with other pathogens, and/or genetic factors. Acute babesia 
infections manifestations include, besides anemia, fever, hemoglobinuria, jaundice, malaise, 
lethargy and anorexia while the chronic status is usually asymptomatic. Nonetheless, these 
surviving hosts frequently become carriers and maintain ticks infection cycle  21.  Babesia spp. 
are responsible for diseases of veterinary and medical importance through transmission by their 
different tick vectors (Table1). 
Table 1. Distribution of several Babesia spp., their main tick vectors and hosts.  
Babesia spp. Main vectors Main hosts Distribution Ref 
B. bovis Rhipicephalus microplus / 
Rhipicephalus annulatus 
Cattle (Bos taurus) 
Africa, America, Asia, 
Australia, Europe 
21 
B. bigemina 
B. ovata Haemaphysalis longicornis Asia 47 
B. divergens * Ixodes ricinus Europe and Asia 48,49 
B. ovis Rhipicephalus bursa 
Sheep (Ovis aries) and 
goat (Capra aegagrus) 
Africa, Asia, Europe 50 
B. gibsoni 
Rhipicephalus sanguineus Dog (Canis lupus) 
Africa, America, Asia, 
Australia, Europe 
39,51,52 
 B. vogelli 
B. microti * Ixodes scapularis 
White-footed mouse 
(Peromyscus leucopus) 
America, Europe and 
Asia 
53–55 
*Human are accidental hosts for these Babesia species. Adapted from: Schnittger et al., 2012 21. 
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1.1.1. Babesia life cycle   
Babesia life cycle is maintained in a complex system of tick vectors and vertebrate 
reservoirs (Figure 1). A generic Babesia life cycle is currently accepted, even though there is 
the major controversy regarding variants across the genus, as reviewed by Jalovecka et al., 2018 
3. In the vertebrate hosts these parasites reproduce asexually within the erythrocytes (merogony) 
and are referred as piroplasms or piroplasmids due to their pear-shaped appearance, sharing the 
term with Theileria, a phylogenetically related protozoan. The initial Babesia sexual stages, 
referred as gametocytes, appear with successful transmission to its vector, reaching the tick 
midgut together with the blood meal, differentiating into gametes. After fertilization these give 
rise to a zygote that undergoes a meiotic division to originate kinetes (gamogony) and a final 
cycle of asexual multiplication originates sporozoites (sporogony), the host-invasive stage, 
guarantying a successful infection of the host. In the tick vector occurs transstadial 
transmission, between the tick stages of development and, for most Babesia spp. transovarial 
transmission is present, a process mediated by parasite invasion of the ovarian cells and 
transmission via larval progeny to tick larvae. Babesia sensu stricto (s.s.) is the informal 
classification for the organisms that exploit this transovarial transmission strategy while 
Babesia sensu lato (s.l.) refers to species that are morphologically similar to Babesia but have 
different life cycle features or cannot be designated either Babesia or Theileria with certainty. 
Nonetheless, this transovarial transmission is recognized as a unique feature among all the 
apicomplexan parasites 3,14,21,25,43,56–59.  
 
Figure 1. Babesia spp. generic life cycle. A susceptible tick, upon its blood meal, ingests these parasites, 
gametocytes, from an infected host. In the tick midgut, they undergo sexual development into mature gametocytes 
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and gametes, whose fusion results in zygotes, able to invade midgut cells. These zygotes go through meiosis and 
differentiate into motile prolonged kinetes, ookinetes, (gamogony) that escape midgut cells and spread to different 
tissues throughout the haemolymph, including the salivary glands. Here, kinetes undergo a cycle of asexual 
multiplication originating sporozoites (sporogony) that will infect a naïve vertebrate host during feeding. The 
infection is maintained throughout tick developmental stages (transstadial transmission). For Babesia sensu stricto, 
kinetes invade tick ovaries and eggs resulting in infected larvae (transovarial transmission). In the vertebrate host, 
upon erythrocytes invasion, parasites reproduce asexually (merogony). 14,21,25. Adapted from: Schnittger et al., 
2012 21. 
1.1.2. Babesia evolution and comparative genomics: applications  
Molecular phylogeny data contributes to more robust Babesia spp. taxonomic 
classifications, establishment of co-evolution patterns with its tick vectors and vertebrate hosts, 
enlightening evolutionary lineages 21,60. Phylogenetic studies using the 18S ribosomal RNA 
(rRNA) gene separates Babesia spp into six broad clades with different degrees of support with 
the clear distinction between two major lineages: Babesia s.s. and Babesia s.l. 21,61. Based on 
this 18S rRNA sequence, B. ovis is placed in Babesia sensu stricto closely related to B. bovis, 
assembling with B. orientalis in a group of moderate support, separated from the branch 
comprising B. bigemina, Babesia ovata, Babesia major, Babesia crassa and Babesia motassi. 
Nonetheless, all of these species are placed in the same phylogenetic clade, clade VI. In a more 
recent study using C1A cysteine proteinases sequences this hypothesis was further supported. 
Also, it has been considered that, within Piroplasmida, the most rapidly evolving lineages are 
those in the clade with B. bovis and B. ovis 21,62–64. 
As an alternative to analyzing 18S rRNA sequences alone, mitochondrial genome 
sequences and structures have proven to be useful for elucidation of evolutionary relationships 
and recently with was possible to identify five distinct Piroplasmida lineages with Babesia spp. 
being assigned to three different groups, referred as the Babesia microti group, the Western 
Babesia group, and Babesia s.s..59. 
Babesia bovis genome was the first to be reported with a total size of 8.6 mega base 
pairs (Mbp) 13. Since then other Babesia species genomes have been sequenced, B. divergens 
(10.8 Mbp), B. bigemina (13.8 Mbp), B. microti (6.5 Mbp), Babesia sp Xinjiang (8.4 Mbp), 
Babesia orientalis and B. ovata (14.4 Mbp) 15,17,18,65,66. B. ovis genome has also been sequenced 
however it is not publicly available 62 . For B. bovis it was found that genome organization and 
structure was remarkably similar to Theileria, presenting microregional similarity to 
Plasmodium falciparum despite the similarities with the last concerning the infection clinical 
outcomes.  
Exploring evolutionary lineages alongside with genome sequencing provides a potential 
avenue to the development of a pan-babesiacidal or even a more wide-range therapeutic 
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strategy. Genomic comparative analyses between T. parva and B. bovis has allowed to identify 
potential antigens in B. bovis that were already under study as vaccine candidates for theileriose 
13,67. Particularly, in B. ovis, a simple gene comparative analysis using C1A family cysteine 
protease sequences from B. bovis, resulted in the identification of  papain-like cysteine protease, 
ovipain-2, an attractive potential vaccine target 68. 
Using the same approach, comparing B. ovata to close related apicomplexan, such as B. 
bigemina, B. bovis, B. microti, P. falciparum and Toxoplasma gondii, allowed to conclude that 
the limited diversity of the ves genes, which encode variant erythrocyte surface antigens 
(VESAs) related with the parasite ability to evade or suppress host immune responses, could 
explain the lower virulence of this species 18. Likewise, this multi-gene family ves in Babesia 
sp. Xinjiang, a species known for having a limited virulence/pathogenicity in sheep was found 
to be substantially distinct both in number and sequence from those of B. bovis, B. bigemina 
and B. divergens 17.  
In sum, genomic comparison facilitates the identification of genes that are undergoing 
positive selection and gene family expansions or contractions providing insights into the 
evolution of gene families and their possible roles in virulence and pathogenicity, which can be 
improved by using model apicomplexan parasites for functional studies 17. The ability to 
genetically manipulate Babesia spp. genome, namely B. ovis, a sheep and goat-infecting 
pathogen phylogenetically close to B. bovis and recognized for having a high virulence for its 
hosts, could be a platform for understanding the role of key molecules in host invasion and 
intra-tick development.  
1.2 Babesia ovis   
Babesia ovis is the main etiological agent of ovine babesiosis, a tick-borne disease of 
small ruminants prevalent in Eastern Asia, Southern Europe (Mediterranean basin), the Middle 
East and Northern Africa, a geographical distribution overlapping the one of its main vector, 
the tick R. bursa 38,69. Ovine babesiosis is an acute disease whose onset is characterized by high 
fever, a scenario that progresses to other clinical symptoms such as hemolytic anemia, 
hemoglobinuria, icterus and, in more severe cases, pancytopenia occurs. The untreated cases 
usually lead to death and even upon treatment the animal may die as a result of a heavy infection 
or suffer a disease relapse after the therapy period 70. Recently, an outbreak has occurred in 
Spain, demonstrating the deleterious effect of B. ovis in naïve sheep transferred from a tick-free 
region to a R. bursa-infested region with endemic piroplasmosis 71.   
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Ovine babesiosis is acknowledged for having an important economic impact related 
with animal mortality, productivity losses (decrease of milk, meat and wool production) and 
costs of the livestock treatment. Particularly for underdeveloped countries, social impact is 
quite significant in the livehood of resource-poor farmers and in food security72,73. The major 
disease control method consists in the use of a babesiacide, imidocarb dipropionate, to manage 
the clinical signs. Even though its efficacy has been long-established, safety issues have 
emerged related with milk contamination and potential carcinogenicity of the drug 74–76. The 
control of the tick vector infestations is another approach to manage this tick-borne disease 
however, emergence of acaricide resistance, including in R. bursa species, exposes the 
vulnerability of this strategy 77. The need for safer and more effective strategies is clear and for 
areas with a B. ovis unstable endemic status, the requirement of an immunization programme 
has been established 77,78. Some efforts were conducted in the context of the development of a 
live attenuated vaccine but the inability to eliminate B. ovis virulence after several blood 
passages invalidates, to date, this therapeutic approach 79. Alternatively, the research paradigm 
can be focused in the development of subunit vaccines that target the reduction of tick 
infestations and block pathogen transmission 80–82. Insight on the molecular interactions in the 
tick-pathogen interplay and the consequent identification of suitable antigenic targets are 
presently key to implement this strategy 83. Research focusing Babesia spp., as well as other 
apicomplexan parasites, encompasses significant constraints such as maintenance of in vitro 
parasite cultures, unavailability of complete and well annotated genomes and practical tools for 
their genetic manipulation 2. Regarding the first, in vitro B. ovis Israeli strain cultures have been 
successfully established (Figure 2), however genome sequencing availability and methods for 
genetic manipulation remain a necessity  84.  
 
 
Figure 2. Babesia ovis forms inside lamb erythrocytes in in vitro cultures. 1. Single round trophozoite. 2. 
Merozoite characterized by piriform shapes forming a pair. 3. Merozoite characterized by piriform shapes 
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forming a tetrad (“Maltese cross” pattern). Intraerythrocytic parasites were observed under a 400x original 
magnification of a Motic BA210 LED trinocular compound microscope (original from the author). 
1.3 Genetic manipulation Methods for Babesia spp. 
Transfection is the process of introducing exogenous nucleic acid molecules (DNA or 
RNA) into eukaryotic cells. The transferred nucleic acid might reside in the cell either stably or 
transiently depending of the nature and destination of the genetic material (Figure 3). Briefly, 
transient transfection techniques are designed to introduce exogenous DNA and short-term 
expression of the foreign genetic material. Thus, the introduced nucleic acid does not integrate 
into the genome of the target cells, and the transfected DNA will not be replicated. On the other 
hand, in stable transfection, the introduced genetic material, that usually has a marker gene for 
selection (transgene) integrates the host genome and maintains the transgene expression along 
host cells replication 85. 
 
Figure 3. Schematic diagrams of two different transfections. (A) Stable transfection. Foreign DNA (red wave) 
is delivered to the nucleus by passage through the cell and nuclear membranes. Foreign DNA is integrated into the 
host genome (black wave) and expressed sustainably. (B). Transient transfection. Foreign DNA is delivered into 
the nucleus but is not integrated into the genome. Triangles are expressed proteins from transfected nucleic acids. 
Black arrows indicate delivery of foreign nucleic acids. Adapted from: Kim et al., 2010 85. 
 
Transfection systems have been developed for several apicomplexan parasites with the 
initial report of the successful application of transfection technology described in T. gondii 86. 
Since then, transient and stable transfection systems were also developed for some Plasmodium 
spp. and for Neospora caninum a transient transfection was promptly developed based on the 
work done with T. gondii 87–89. For Babesia spp. such manipulation emerged in the last decade 
after availability of B. bovis genome sequence with reports of  transient transfections system 
for this specie 136,90–92. A stable transfection system for B. bovis was developed and it is 
currently acknowledged that for at least T. gondii and B. bovis a stable transfection baseline 
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protocol was defined 2,93. More recently, transient transfection systems followed by stable 
transfection were performed in B. ovata after the unravelling of its genome 18,94. Similarly, 
stable transfection systems have been developed for B. bigemina and B. gibsoni 95–98 (Figure 
4).  
 
 
Figure 4. Timeline of selected landmark publications on the development of transient and stable transfection 
systems in Babesia spp.  indicates transient transfection system.  
 
Transient transfection systems establishes the appropriate parameters for introduction 
of the exogenous DNA (definition of an electroporation/nucleofection protocol that carries the 
minor impact for the parasite) and, more importantly, permit to identify and test function and 
efficacy of promoter and termination signals (regulatory elements) mediating gene expression 
and regulation 6,99. In fact, these systems were essential to find suitable promoters in Babesia 
spp. and to reveal the existence of promoters with interchangeable cross-species function 
6,94,95,97,100. The establishment of a stable transfection system demands, besides the 
aforementioned criteria, to identify a suitable genetic marker to select the transgenic parasites 
(a selectable marker) and the preparation of a cassette containing the defined selectable marker 
gene along with suitable targets for DNA integration, whose disruption does not compromise 
the parasite viability 6,2 . Therefore, to establish a stable transfection system for B. ovis that 
enables the expression of a fluorescent reporter protein, the methodology followed should be 
similar to the ones used previously for transgenic- Babesia spp., following the steps described 
in figure 5.  
B. bovis (Suarez 
et al., 2004) 
B. bovis 
(Suarez et al., 2009) 
B. ovata 
(Hakimi et al., 2016) 
B. bigemina 
(Silva et al., 2016) 
B. bigemina 
(Silva et al., 2018) 
B. gibsoni 
(Liu et al., 2017) 
B. gibsoni 
(Liu et al., 2018) 
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Figure 5. Flowchart describing the steps required for the development of a stable transfection system for 
Babesia ovis. Adapted from: Suarez et al., 2010 6. 
 
1.3.1. DNA transfer system: nucleofection  
There is a huge methodological diversity concerning transfection, with the several 
strategies being broadly classified as biologically, chemically, and physically mediated 
methods 85. Herein, focus will be on a physical method, electroporation, since it is regarded as 
the most robust and reproducible method to transfect Apicomplexan parasites 101.  
Electroporation is the most commonly used physical method of DNA delivery and its 
exact mechanism is unknown. However, it is suggested that a short electrical pulse disturbs cell 
membranes, creating holes through which nucleic acids can pass.  It is accepted that it occurs 
through a multistep mechanism that relies not only on the plasma membrane permeabilization 
but also in the electrophoretically driven interaction between the DNA molecule and the 
destabilized membrane, both mediating its passage across the membrane and, once inside the 
cell, its migration towards the nucleus 85,102.  
Babesia merozoites are obligatory intraerythrocytic organisms thus, a successful 
transfection approach must be able to transfer the exogenous DNA through the erythrocyte, 
merozoite and nuclear membrane layers. This results in a severe impairment in DNA delivery 
as seen in the low transfection efficiencies for this parasite and related apicomplexan 92,103,104. 
For B. bovis the process of developing a transient transfection system involved the 
determination of suitable electroporation parameters and later a comparison between that 
process and nucleofection, a novel electroporation based method 92,99. Nucleofection consists 
in a transfection method that combines a specific nucleofector solution and specific electrical 
parameters to successfully deliver DNA into the nucleus. It is though that during nucleofection 
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a square wave pulse is produced which improves pore-formation and enables the incorporation 
of exogenous DNA in the nucleus without cell division 101,105. 
Nucleofection has resulted in higher transfection efficiencies and enhanced parasite 
viability in Plasmodium 106,107. For B. bovis it was shown that nucleofection was more efficient 
for the delivery of smaller plasmid DNA amounts and the inverse occurred with electroporation 
in which efficiency would increase concomitantly with the amount of DNA to deliver (to a 
maximum plateau of 200 μg), whereas delivery of 20 μg of DNA corresponded in both methods 
to similar relative efficiencies. Regarding the detrimental effects of any of the methods for the 
parasite it was shown that nucleofection provided a superior parasite viability 6,99,104.  
Electroporation and nucleofection have been used for transfection of several Babesia 
spp. but an optimization of the electroporation parameters for the first and the assessment of 
the best nucleofector solution for the latter needs to be performed. For B. bovis it was 
suggested that nucleofector program v-024 in combination with “Plasmodium” buffer was 
optimal and for B. ovata the same program in conjunction with Amaxa nucleofector human 
T-cell solution was used to stably transfect the parasite in a Nucleofector™ 2b Device, an 
association also used to stably transfect B. bovis 7,92,94,108. On the other hand, B. gibsoni was 
stably transfected using an optimized protocol consisting of Lonza buffer SF associated 
program FA113 of Amaxa 4D Nucleofector™ device 98,100. For B. bovis, optimized 
electroporation settings (1.2 kV/ 25 µF/200 Ω) have been used successive times to transfect 
this parasite and the same protocol was used to stably transfect B. bigemina 6,10,93,96. 
1.3.2. Regulatory sequences 
1.3.2.1. Promoter regions and transcription start sites  
The identification of transcription start sites (TSSs) is crucial for in-silico gene 
discovery, to understand transcription regulation mechanisms and to aid in the definition of the 
core promoter109–111. The latter, allied to the identification of cis-regulatory elements, binding 
sites for proteins involved in transcription initiation and regulation, it is essential to define the 
size of the isolated promoter for cloning. This information is key for the development of more 
efficient systems for transient and stable transfection 112,113. Nonetheless, it must be taken in 
account that gene expression can also be regulated at post-transcriptional and translational 
levels, but little is known about this modulation in apicomplexan parasites. In P. falciparum the 
correlation between mRNA and protein expression is found moderately positive even though 
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there is some delay in some genes expression indicating the existence of such regulatory 
mechanisms 114,115. 
 It is known that for every eukaryotic gene there is a core promoter region in the 5′ 
untranslated region (UTR) containing ate least one TSS signal to which binds the RNA 
Polymerase 2 (Pol-II). Particularly, the 5′ UTRs between TSSs and the first in-frame initiation 
codons are recognized for modulating RNA stability through action of internal ribosome entry 
sites (IRESs) or riboswitches. This region, for B. bovis, has a median length of 152 bp, similar 
in size with the one from T. gondii (130 bp) 113,116–118. This gene-proximal region is crucial for 
a nominal gene expression and additional upstream sequences enhance the promoter activity 
119.  
In B. bovis a TSS initiator-like motif TYAYWWW has been identified, probably a 
binding site for the general transcription factors TAF1 an TAF2, and also other location-specific 
consensus motifs, cis elements, have been found, probably crucial for binding to other 
transcriptional factors 113.  
The apicomplexan parasites transcriptional machinery is recognized for differing from 
other eukaryotes, in which the absence of canonical eukaryotic transcription factors is 
particularly noticeable 113,120–124. Additionally, it is acknowledged that apicomplexan 
transcription machinery is not able to recognize viral promoters, such as the cytomegalovirus 
(CMV) and simian virus 40 (SV40) that are widely used to produce heterologous transfection 
systems 125,126. 
Herein, the most used promoter regions in Babesia spp. to drive expression of 
exogenous genes: the 5’ flanking region of the actin gene (5’ act) and the elongation factor-
1 alpha intergenic region (ef-1α IG) will be focused. The 5’ act has been used to drive 
expression of the selective marker cassette in stably transfected B. bovis and B. ovata 7,94. More 
recently it was shown that 5’ act from B. gibsoni presents higher activity in B. bovis than its 
homologous promoter and this promoter region was interchangeably functional between B. 
bovis and B. gibsoni127. The ef-1α IG contains a recognized strong constitutive promoter signal 
91,128. In B. bovis and B. bigemina the ef-1α locus consists in two identical ef-1α genes arranged 
in a head to head orientation separated by a 1.4 kb IG, structurally similar to the locus found in 
Plasmodium genome. Apparently, the IG contains two independent promoters (ef-1α IG-A and 
ef-1α IG-B) regulating bidirectional transcription of the two ef-1α open reading frames (ORFs), 
a bidirectional activity first described in P. berghei 91,95,129,130 Therefore, a rational approach for 
the identification of B. ovis ef-1α promoters consists in searching for this locus in its genome. 
The most active promoter region within the ef-1α IG region consists in a 710 bp region located 
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upstream the ef-1a gene B, the ef-1α IG-B 6,91. This promoter region has been used to drive 
stable expression of a green and a red fluorescent-blasticidin deaminase-S (GFP-BSD and RFP-
BSD) fusion proteins in B. bovis merozoites 93 and GFP expression in B. ovata and B. gibsoni 
94,98. Remarkably, the bidirectional transcription activity was used to express simultaneously a 
GFP-BSD and a tick antigen, being this the first experience of expression of a foreign antigen 
in a transfected B. bovis delivery platform, thus a live-vector vaccine 10,128,108.  
Recently, it was found that promoters previously identified in B. bovis ef-1α IG region 
are also functional in B. bigemina and ten interchangeable cross-species functional promoters, 
including ef-1α IG-B, were identified between B. gibsoni and B. bovis 100. Interestingly, the ef-
1α IG heterologous promoter sequence showed to be more efficient driving expression of the 
reporter luciferase than the homologous promoter in B. bigemina, and similar results were found 
in the latter study with B. gibsoni 5’ act being more active than the homologous promoter in B. 
bovis 95,100. Finally, a study in B. bovis suggests that the use of heterologous regulatory regions 
such as cross-species functional promoters increases the specificity of the genome integration 
event 8. Since the B. ovis genome is currently unavailable, these findings together with the 
availability of other genome sequences from Babesia spp., particularly the one of its 
phylogenetically close B. bovis, provides a solid working basis for the present study 16,65,77, 
95,100.  
1.3.2.1. Transcription termination regions  
Transcription termination in eukaryotes consists in the release of the Pol II together with 
the nascent RNA from the DNA template, however the underlying molecular mechanisms are 
still under study 120,131,132.  Transcription termination is assumed to occur the same way as in 
the yeast system model, with the Pol II continuing transcription after the polyadenylation signal 
(PAS). Then, a succession of allosteric protein-protein interaction end in the transcript cleavage 
11-30 bp downstream the PAS 120,132. Around the transcription termination site, it has been 
observed, for the apicomplexan T. parva, the presence of over-represented motifs, some of them 
with the potential to produce a stem-loop structure (hairpin), possibly having a structural role 
in transcription termination 120,133. 
The intergenic regions in the rhoptry associated protein-1 (rap-1) locus were used for 
the first transient transfection system in B. bovis promoting exogenous gene expression 90. 
However, it was demonstrated that rap-1 promoter signals were relatively weak and potentially 
unsuitable for the development of a stable transfection system that would require a high level 
expression of the exogenous gene (able to confer resistance to a selectable marker) 90,91. 
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Therefore, the following transfection constructs developed for Babesia spp. used the rap-1 
intergenic regions for its termination signals 6,94,95,97. Studies of rap-1 locus organization have 
been conducted for several Babesia spp., revealing that the rap-1 family consists in multiple 
gene copies arranged in tandem and separated by IG regions 134. In B. ovis, the rap-1a locus is 
partially described, pointing towards the existence of 5 closely linked genes (Bo60.1 – Bo60.5) 
with an apparent high sequence conservation between genes Bo60.1-60.4 and lower similarity 
to 60.5 135.  
Currently, three rap-1 genes in Babesia spp. designated rap-1a, rap-1b and rap-1c are 
described. However, it appears that this feature is confined to a phylogenetic group comprising 
B. motassi-like and B. bigemina 136,137. In B. ovis all the copies have been assigned as rap-1a 
with two different gene types within this designation (rap-1a60-1-4 and the type rap-1a60-5). 
In a recent study it was verified that RAP-1a sequences from B. sp. Xinjiang formed a clade 
with B. ovis, B. bovis and B. orientalis clustering with all the babesial RAP-1a type sequences 
136. Recent work with B. gibsoni transfection indicated that B. bovis 3’ rap-1a has cross-species 
function even though the interchangeability was not tested 100. Exploring B. ovis rap-1 locus 
can give a better insight in its structure, important not only to use the IG region for transcription 
termination but also because RAP-1 proteins have been proposed as a potential candidate for 
the development of recombinant vaccines against babesiosis due to their implication in 
erythrocyte invasion and high immunogenicity 134,136. Assessing the number of rap-1 copies in 
B. ovis genome would also provide more information to study this region regarding its 
importance as a virulence factor 138. 
1.3.3. Selectable markers  
The development of a stable transfection system requires the identification of an 
appropriate genetic marker in order to select the transgenic parasites, i.e., a selectable marker 
2,6. The firsts reports of stable transfection in apicomplexan parasites, namely Plasmodium, used 
the WR99210/ human dihydrofolate reductase (hdhfr) selection system 139. The enzyme 
dihydrofolate reductase (dhfr) has been a target for several anti-malarial drugs since its 
inhibition depletes the parasite reduced folate pool, blocking de novo thymidylate biosynthesis 
by thymidylate synthase, and eventually preventing DNA synthesis 140. The 4,6-diamino-1,2-
dihydro-1,3,5-triazine WR99210 is not available as anti-malarial drug due to its high toxicity, 
however it was used to successfully select transgenic P. berghei parasites harbouring the 
hDHFR gene, since this gene conferred resistance to the antifolate drug 141. 
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The first attempts to stably transfect B. bovis used the same strategy, however naturally 
resistant parasites to WR99210 emerged 6. In fact, B. bovis contains a copy of the dhfr enzyme 
gene, required for synthesis of precursors of purines and thymidylate. Moreover, it was found 
out that the presence of polymorphic versions of this gene, such as the single amino-acid change 
present in B. bovis dhfr enzyme, renders the parasite resistant to antifolate drugs, namely 
WR99210 13,140.  Interestingly, subsequent studies were able to select transgenic-B. bovis 
parasites and more recently, this strategy was used to select transgenic-B. ovata and transgenic-
B. gibsoni 7,94,98,108. 
The blasticidin/blasticidin-deaminase (bsd) selection system has been described for 
effective selection of transgenic-Plasmodium parasites and it was the first system used to select 
stably transfected B. bovis parasites 93,142. Blasticidin S is a nucleoside antibiotic able to inhibit 
protein synthesis in both prokaryotes and eukaryotes 143. For parasites infecting an anucleate 
host erythrocyte the drug concentration range is not restrained by toxic effects in the host cell 
142,144. Also, there are no bsd homologous genes in B. bovis genome and experimental evidence 
demonstrated that B. bovis was highly susceptible to blasticidin, supporting it as a good 
selection system 13,93. In B. bigemina blasticidin-S was also used as a suitable selective 
inhibitory drug 96.   
The previous reports support the evaluation of B. ovis sensitivity to WR99210 and 
blasticidin-S to assess the suitability of these selection systems. 
1.3.4. Genome integration targets  
The integration of exogenous DNA into a specific genome region depends on 
homologous recombination mechanisms, a process that consists in the exchange of genetic 
information between two identical DNA sequences 145. The existence of different patterns of 
processing transfected genes has been proposed for Toxoplasma, Plasmodium and Babesia, as 
it heavily depends of their available DNA repair mechanisms 8,146. Gene targeting in 
Toxoplasma parasites is innately ineffective due to the ability of randomly inserting the foreign 
DNA in different sites from the specifically targeted due the existence of a non-homologous 
end joining mechanism, a problem solved by knocking out KU80, an important component of 
the pathway 147. In contrast, for Plasmodium, the process of exogenous DNA integration 
depends exclusively on homologous recombination mechanisms, as reviewed by Limenitakis 
and Soldati-Favre (2011) 101.  Even so, for Plasmodium, gene targeting is still quite inefficient 
due to the unique richness of A + T of its genome that impairs efficient exogenous DNA 
integration 104.  
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Babesia and Plasmodium both present homologous recombination mechanisms and the 
random insertion of exogenous genes appears to be rare, however Plasmodium parasites can 
use both single and double cross- over insertion recombinant mechanisms whereas for Babesia 
it is demonstrated in several transfection studies that gene insertion occurs exclusively through 
a double crossover mechanism 7,8,93,94,96,98,101,108,148 (Figure 6). Thus, Babesia spp.- specific 
transfection appears to be an efficient genetic manipulation technique 8. 
The first report of a stable transfection system for B. bovis targeted one of the ef-1α gene 
copies and, several posterior transfection studies confirmed the successful and specific 
integration in this site 7,93,94,96,98,108. Furthermore, the disruption of one of the two ef-1α gene 
copies by a double-crossed homologous recombination mechanism in several Babesia spp. did 
not affect parasite viability and the growth of the transfected isolates is comparable to the wild-
type parasite 93,94,96,98. An identical ef-1α locus arrangement in B. ovis genome is expected 
supporting the feasibility of using this locus for exogenous gene integration.   
 
Figure 6. Schematic representation of a stable transfection construct integrating elongation factor-1alpha 
open reading frame-B through a double crossover recombination event. A. Stable transfection construct with 
elongation factor 1α (ef-1α) promoter driving expression of a cassette comprising a reporter gene and a selectable 
marker gene with 3’ rhoptry associated protein-1 (3’ rap-1) as terminator B. Representation of the ef-1α locus in 
a transfected parasite line.  represent enzyme restriction sites for plasmid linearization. 
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2. Objectives  
The main goal of this project was the development of a stable transfection system 
driving expression of a fluorescent marker for B. ovis. 
In order to achieve this goal, the following specific aims were established: 
1. Identification of suitable regulatory elements in B. ovis genome and/or identification of their 
heterologous in other Babesia spp; 
2. Construction of transient transfection plasmids with the previously selected promoter 
regions, driving expression of a reporter luciferase; 
3. Evaluation of transfection process parameters, transfection efficiency and promoter activity; 
4. Identification of a suitable selection system for B. ovis transfectants; 
5. Construction and validation of a transient transfection system for B. ovis with the previously 
selected promoter driving expression of a fusion protein expressing the fluorescent and 
selectable maker genes; 
 
This study represents a step forward in the development of methods for B. ovis genetic 
manipulation, an undoubtedly necessary tool to study this parasite basic biology, including its 
life cycle, the parasite interactions with host cells and virulence factors.   
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3. Materials and Methods  
3.1. In vitro Babesia ovis cultures 
B. ovis in vitro cultures were established in biosafety level 2 facilities at Instituto de 
Higiene e Medicina Tropical (IHMT), following an adapted protocol from Vega et al 84. Briefly, 
cryopreserved B. ovis (Israeli strain) infected red blood cells (iRBC) at 8% parasitemia were 
used to initiate the culture. Parasites were cultured in 10% (vol/vol) defibrinated lamb 
erythrocytes (commercialized by Biorabbit, Lisbon, Portugal) maintained in a HEPES-buffered 
Medium 199 (1x) supplemented with Earle's Salts, L-glutamine and L-Amino acids (Gibco, Life 
technologies, Thermo Fischer Scientific, Waltham, Massachusetts, USA). Culture complete 
medium was further supplemented with 20% (vol/vol) lamb serum (Gibco, Thermo Fischer 
Scientific) and Antibiotic-Antimycotic (100x) at a final concentration of 0,05 µg/mL 
amphotericin, 20 U/mL penicillin and 20 μg/mL streptomycin (both from Gibco, Thermo 
Fischer Scientific), 1 mM L-cysteine-HCl, 2 mM bathocuproine-disulfonic acid and 25 mM N-
Tris (hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) (all from Sigma-Aldrich, St. 
Louis, MO, USA) 73.  
Vega y Martinez (VYMS) solution was used for washing and storage lamb erythrocytes 
for up to 5 weeks and the cryoprotectant used to freeze parasite culture was 20% 
polyvinylpyrrolidone-40 (PVP-40) (Sigma-Aldrich) in VYMS solution 149. 
Parasite culture was maintained in a microaerophilic stationary phase atmosphere (5% 
CO2, 2% O2 and 93% N2) at 37ºC  using a modular incubation chamber, as described elsewhere 
73. In a daily basis, 80 % of the medium was replaced and culture parasitemia was monitored 
by preparation of thin blood smears stained with Hemacolor® Rapid staining of blood smear 
(EMD Millipore, Darmstadt, Germany). Intraerythrocytic parasites were observed under a 400x 
original magnification of a Motic BA210 LED trinocular compound microscope. 
3.2. Evaluation of Babesia ovis sensitivity to WR9910 and blasticidin-S 
B. ovis parasites were cultured in 1 mL of culture medium containing 10% lamb RBC 
(RBC suspension) in 24-well plates (Corning Costar, Corning, New York, USA). For WR9910 
sensitivity assay, drug concentrations of 0.5, 1, 5, 10 and 50 nM were prepared from a 0,017 M 
stock solution of WR99210 (Sigma-Aldrich) in 100% dimethyl sulfoxide (DMSO), as done 
elsewhere 94. Negative control was performed only with the drug vehicle to a final concentration 
of 0.1 % (v/v), the same DMSO concentration of the wells subjected to drug pressure150. For 
blasticidin-S, drug concentrations of 0, 1.2, 2.4, 4.8, 7.2, 9.6, 12, 14.4, 19.2, 24 and 28.8 µg/mL 
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were prepared from a 5 mg/mL blasticidin-S (Panreac AppliChem, ITW reagents, Barcelona, 
Spain) stock solution as done elsewhere96.The drug vehicle, sterile water, was used as negative 
control.  
The initial percentage of parasitized erythrocytes (PPE) for all the sensitivity assays was 
approximately 1% and it was achieved artificially by diluting the ongoing B. ovis culture with 
an appropriate volume of RBC suspension.  
 Parasites were cultured in triplicate for each drug concentration and 80% of the culture 
medium was replaced daily by fresh medium with the appropriate drug concentration.  PPE was 
calculated at 24 h, 48h and 72h by examining at least 1000 RBCs of a prepared thin blood smear 
stained as described in section 3.1. To calculate the % of B. ovis growth inhibition and the 50 
% inhibitory concentration (IC50) the following formula was used, as done elsewhere 
93:  
 
Mean PPE in control wells-Mean PPE in blasticidin-S treated wells 
Mean PPE in control wells
  𝑥 100 
 
3.3. Bacterial strains, plasmids and growth conditions  
Bacterial strains and plasmids used in the present study are listed in Table 2. E. coli was 
grown at 37ºC in Luria-Bertani (LB) broth with shaking or agar151. Super Optimal broth with 
Catabolite repression (S.O.C.) (2% tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was also used when appropriated. 
Supplementation with 100 g mL-1 ampicillin (Panreac AppliChem) or 50 µg mL-1 kanamycin 
(Sigma-Aldrich) was carried out for transformants selection. Cell concentrations were 
estimated by measuring the optical density (O.D.) at 600nm (O.D.600) using a 
spectrophotometer (Biophotometer-Eppendorf).  
Table 2. Strains and plasmids used in the present study. 
Strains and plasmids Description 
Reference 
/Source 
Escherichia coli 
JM109 
recA1 endA1 gur96 thi hsdR17 supE44 relA1 Δ(lac-
proAB) [F’ traD36 proAB lacIqZΔM15] 
Stratagene 
TOP10F’ 
F′ [lacIq, Tn10(TetR)] mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
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Strains and plasmids Description 
Reference 
/Source 
Plasmids 
pLVX-TetOne™-Puro-
Luc 
Inducible Lentiviral expression vector of 
Photinus pyralis Luciferase reporter gene. AmpR 
Clontech 
pCRTM-Blunt I 
TOPO vector 
A linearized and topoisomerase I-activated vector for 5
-minute benchtop ligations without ligase with a ccdB  
gene for positive selection of recombinants. KanR 
Invitrogen 
TOPO-RV1RV3 
Cloning of the PCR product resultant from  
amplification with primers PR-Ef-ORF-B-RV1 and PF-
Ef-ORF-B-RV3 in pCRTM-Blunt I TOPO vector . KanR 
This study 
TOPO-rap 
Cloning of rhoptry associated protein gene and 3' end 
 in pCRTM-Blunt I TOPO vector . KanR   
This study 
pBrfp-bsd 
Plasmid with B. bovis ef-1α IG-B region driving 
expression of rfp-bsd gene, a fusion protein comprising 
a red fluorescent protein and blasticidin-S deaminase 
(selectable marker). AmpR 
108 
pBef1αIG2 
Plasmid with B. ovata IG-B region driving expression 
of Renilla Luciferase Reporter gene. AmpR 
94 
pBbovis-luc 
pBrfp-bsd with B. bovis ef-1α IG-B region driving 
expression of Luciferase reporter gene. AmpR 
This study 
pBovata-luc 
pBef1αIG2 with B. ovata IG-B region driving 
expression of Luciferase reporter gene. AmpR 
This study 
pBS-luc pBovata-luc without B. ovata IG-B region. AmpR  This study 
pBovata-rfp-bsd 
Plasmid with B. ovata IG-B region driving expression 
of rfp-bsd gene. AmpR 
This study 
3.4. Preparation and transformation of chemically and electrocompetent cells  
Preparation of electrocompetent cells of E. coli was performed according to Smith et 
al.152 Briefly, a culture reaching an OD600 of 0.6-0.7 in LB was centrifugated to form a cell 
pellet and washed 3 times with 10% ice-cold molecular biology grade glycerol (AppliChem). 
After the last centrifugation step, cells were concentrated 250-fold in 10% ice-cold glycerol. 
Electroporation was carried out in a Gene Pulser® Electroporation System (Bio-Rad) using a 
pulse of 1.8 KV, 25 μF and 200 Ω for 0.2 cm cuvettes or 1800 V, 25 µF and 200 Ω for 1 mm 
cuvettes. 
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Chemically competent cells were prepared following the Hanahan method 153. Briefly, 
a culture with an OD600 of ≈ 0.4 in LB was pelleted, washed once with 50 mM ice-cold CaCl2 
solution and cells were concentrated 10-fold in ice-cold 50 mM CaCl2-15% glycerol. All 
competent cells were frozen and stored at -80ºC until further use.  For chemical transformation 
cells were centrifuged and resuspended in 50 mM CaCl2 before transformation which was 
carried out by heat shock, incubating cells with the appropriate DNA, on ice for 30 min and 
then placing them in a 42ºC water bath for exactly 2 min.  
3.5. Babesia ovis DNA extraction  
Parasite culture was centrifuged for 5 min. at 200 G, infected-RBCs (iRBCs) pellet was 
resuspended in 500 µg/mL trypsin in phosphate buffered saline buffer (PBS) and incubated at 
37ºC for 20 min. Complete medium was added in a 1:1 proportion to the pellet and mechanical 
lysis of erythrocytes was performed by ten passages through a 26-gauge needle.  The 
suspension was after centrifuged for 5 min/1500 G, to retrieve released B. ovis in the 
supernatant. Genomic DNA extraction was proceeded using NZY Blood gDNA Isolation Kit 
(NZYTech, Lisboa, Portugal), following manufacturers’ instructions and genomic DNA eluted 
in 50 μL of manufacturers’ provided elution buffer.  
3.6. PCR, enzymatic restriction and purification 
 DNA fragments were amplified by PCR using the NZYTaq 2x Green Master Mix 
(NZYTech), unless high fidelity PCR products were required. For the latter, DNA polymerases 
with proofreading activity were used: Pfu DNA Polymerase (Promega, Madison, Wisconsin, 
USA), NZYSpeedy Proof DNA polymerase (NZYTech, Lisboa, Portugal) or iProof™ High-
Fidelity DNA Polymerase (Bio-Rad, CA, USA). PCR amplifications were carried out 
accordingly to manufacturers’ instructions in standard thermocyclers (Applied Biosystems 
SimpliAmp or Bio-Rad T100 Thermal Cycler). The amplification products were analysed by 
electrophoresis in 0.8 to 1.2% (w/v) agarose gels containing GreenSafe Premium (NZYTech) 
or ethidium bromide and using 0.5X TBE as electrophoresis buffer. Gels were analysed under 
UV light and pictures were acquired using ChemiDoc system (Bio-Rad). The fragments size 
was estimated by comparing with DNA ladders (NZYDNA Ladder VI, VII and VIII, NZYTech; 
or GeneRuler 1 kb DNA Ladder, Thermo Scientific) run along with DNA samples.    
DNA fragments obtained from PCR amplification or enzymatic restriction products were 
purified using QIAquick PCR purification Kit (Qiagen, Hilden, Germany), NZYGelpure Kit 
(NZYTech) or GRS PCR & Gel Band purification Kit (Grisp, Porto, Portugal), following 
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manufacturers’ instructions. Isolation and recovery of DNA fragments or digested vectors run 
in low-melting point agarose gel (SeakemTM LE agarose, Lonza, Basel, Switzerland) stained 
with ethidium bromide were purified using NZYGelpure Kit (NZYTech). 
Plasmid DNA extraction and purification was performed with NZYMiniprep kit 
(NZYTech), following the protocol recommended by the manufacturer. DNA was eluted in the 
minimal volume of sterile distilled water and stored at -20ºC. Restriction enzymes 
(FastDigest®, Fermentas) and T4 DNA ligase (New England Biolabs) were used according to 
supplier’s instructions.  
DNA concentration and purity (analysis of A260/A280 ratio) was estimated using a ND-
1000 Spectrophotometer (NanoDrop ND1000, Thermo Fisher Scientific, Waltham, MA).  
3.7. Amplification, cloning and sequencing   
To construct plasmids TOPO-RV1RV3 and TOPO-rap, amplicons generated by PCR 
with primers PR-Ef-ORF-B-RV1/ PF-Ef-ORF-B-RV3 and Rap1α-Dissimilar-FW/ Rap1-3-RV, 
respectively, conjointly with Pfu DNA polymerase (Promega) were cloned into the pCRTM-
Blunt I-TOPO vector (Invitrogen, Thermo-Fisher Scientific). The recombinant plasmids were 
transformed into TOP10 chemically competent E. coli, following the Zero Blunt TOPO PCR 
Cloning kit instructions. Ten colonies were selected for colony screening PCR and the inserted 
fragment was checked with Supreme NZYTaq II DNA polymerase (NZYTech, Lisboa, 
Portugal) using the appropriate primers. A single colony was then picked and grown overnight 
in S.O.C medium containing kanamycin (50 µg/mL), at 37ªC with shaking (180 rpm). Plasmid 
DNA extraction and purification was carried out as described in section 3.6 and presence of the 
insert was further analyzed by restriction analysis using BamHI and XhoI restriction enzymes. 
The recombinant vectors containing the fragments of interest were sent to Sanger sequencing 
at GATC Biotech (Ebersberg, Germany) with the universal primers M13 Forward (-20) and 
M13 Reverse. 
3.8. Screening for suitable regulatory regions in Babesia ovis genome  
The 5’ flanking region of the actin gene was explored using the available sequences of 
B. bovis and B. bigemina actin gene (GenBank accession numbers AK441690 and 
XM_012912903). Basic Local Alignment Search Tool (BLAST) was used to search sequences 
in EuPathDB: The Eukaryotic Pathogen Genomics Resources (https://eupathdb.org/eupathdb/) 
to retrieve the upstream non-coding region of B. bovis and B. bigemina actin gene. Searches 
with the MEME Suite 5.0.2 used motif length constraints of 5 bp to 15 bp, searching both 
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strands at the DNA level for a maximum of 10 motifs with an E-value cut-off of 0.05 assuming 
zero or one occurrence of a motif as has been done previously 120,154 The search was 
complemented with the use of FIMO version 5.0.2 program to search for particular motif 
occurrences 155. 
The sequences from B. bovis, B. bigemina and B. divergens (GenBank accession 
numbers: DQ322644, KT439182 and LK934712, respectively) were used to explore the B. ovis 
ef-1-α locus. The rap-1 locus was also analyzed for transcription termination using the B. ovis 
rap-1 locus partially described (GenBank accession numbers: M91169, M91170, M91172, 
M91173, M91174 and M91176)135. Primers aiming the sequencing of unknown regions and the 
understand of B. ovis rap-1 locus organization were manually designed.   
The oligonucleotides used for all the strategies aiming amplification and sequencing of 
B. ovis 5’ actin, ef-1-α and rap-1 locus were evaluated using the OligoAnalyzer from Integrated 
DNA technologies ( https://eu.idtdna.com/calc/analyzer ) and are listed in table 3. 
 
3.8.1. Methodologies for Babesia ovis elongation factor-1α and rhoptry associated protein-1 
intergenic regions locus assembly  
The strategies developed to assemble B. ovis ef-1α locus were based on an initial 
analysis of ef-1α-B gene sequences from B. bovis, B. bigemina and B. divergens using  the 
bioinformatics tool: Clustal Omega multiple sequence alignment program 
(https://www.ebi.ac.uk/Tools/msa/clustalo/ ) 156. A set of reverse primers (PR-Ef-ORF-B-
RV1/ PF-Ef-ORF-B-RV3) were manually designed to take advantage of the head to head 
orientation for intergenic region PCR amplification, as done elsewhere 157. Also, to proceed to 
a PCR-mediated genome walking method the set of primers PF-ef-ORFB/PR-Ef-ORF-B were 
manually designed to amplify part of ef-1α-B gene (Figure 7) 156. 
 
Figure 7. Expected organization of Babesia ovis elongation factor-1alpha locus based on Babesia bovis 
sequence. Primers PR-Ef-ORF-B-RV1 and PR-Ef-ORF-B-RV3 hybridization sites in ef-1α-B gene are represented 
with yellow and blue arrows, respectively. Grey arrows represent primers hypothetical hybridization sites in ef-
1α-A gene. Expected orientation of the open reading frames (ORF) is shown with black dashed arrows. (not for 
scale).  Adapted from: Suarez et al., 2006 91.  
PR-Ef-ovis-specific was designed to hybridize in B. ovis ef-1α-B gene sequenced region 
for PCR amplification with non-specific primers targeting the ef-1α-B 5’ flanking region (PF-
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Ef-IG1 and PR-Ef-IG3). This strategy intended  to amplify the promoter region upstream ef-
1α-B gene (Figure 8), as described elsewhere 158,159.  
 
Figure 8. Scheme of the PCR-mediated genome walking method for Babesia ovis elongation factor-1alpha 
locus. A sequence specific primer, PR-Ef-ovis-specific, was designed from ef-1α-B gene known sequence (blue 
box) to generate a PCR product with non-specific primers designed from B. bovis ef-1α IG sequence (PR-ef-IG1 
and PR-ef-IG3) that anneal in B. ovis genome under a low annealing temperature. Hybridization sites of primers 
are shown (not for scale). Expected orientation of the open reading frame (ORF) is shown with a black dashed 
arrow.  
The approach to understand B. ovis rap-1 locus, consisted in the design Rap1α-
Dissimilar-FW, hybridizing in a region found dissimilar between the available rap-1 gene 
copies sequences using the Clustal Omega multiple sequence alignment program 156 and a 
primer reverse hybridizing in  rap-1 60.5 3’ end, Rap1-3-RV. 
Table 3. Primers used for amplification and sequencing of Babesia ovis elongation factor-1alpha and rhoptry 
associated protein-1 locus  
Primer name Sequence (5’→3’) 
Primers used to amplify Babesia ovis actin gene 
PF-actin-gene CCAAAGAACCCTGCCCTTAT 
PR-actin-gene GACGATGTTGGGTCCAGCCT 
Primers used to amplify Babesia ovis elongation factor-1alpha locus 
PR-Ef-ORF-B-RV1 GCCAATAACGACCAAGTTAATGTG 
PR-Ef-ORF-B-RV3 ACAACAAGCATAGCAACATCGG 
PF-Ef-ORF-B CAAGTACGCCTGGGTTTTGGAC 
PR-Ef-ORF-B CGGTACGCTTGTCCATACGG 
PF-Ef-IG1 TATCAAAAACACACAATACT 
PR-Ef-ovis-specific CACGTTCACGCTCACTCTTCAGC 
PF-Ef-IG3 CACGTAATAAATGAGAT 
Primers used to amplify Babesia ovis rhoptry associated protein 1 locus 
Rap1α-Dissimilar-FW CGCACCAAGGACTTCTTC 
Rap1-3-RV GAATTCGTTAAGCTCGGTGA 
Primers for sequencing 
M13 Forward (-20) GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
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3.9. Transient transfection plasmid constructs 
The ability of B. bovis and B. ovata ef-1α IG-B regions to function as heterologous 
promoters was evaluated through expression of a firely luciferase (luc) gene in B. ovis. For this, 
two transient transfection constructs were developed, the pBbovis-luc and pBovata-luc.  
The pBrfp-bsd (Table 2) (kindly provided by professor Masahito Asada) was used as 
backbone for development of pBbovis-luc construct. Linearized vector containing only B. bovis 
ef-1α IG-B sequence was obtained by enzymatic restriction with EcoRV and BamHI and was 
isolated and purified from a 0.8% low-melting point agarose gel as described in section 3.6. 
The luc gene was amplified by PCR from pLVX-TetOne™-Puro-Luc (Table 2) with primers 
PF-luc-EcoRV/ PR-luc-BglII and the 3’ rap-1 terminator sequence with primers PF-bovis-
rap-1-BglII/ PR-bovis-rap-1-BamHI (Table 4). Both purified PCR products were digested 
with BglII restriction enzyme, followed by a ligase reaction.  After enzyme inactivation (65 ºC 
for 10 minutes), PCR amplification of luc-3’rap-1 cassette with primers PF-luc-EcoRV/ PR-
bovis-rap-1-BamHI was performed as done elsewhere 160. The amplified fragment was then 
digested with EcoRV and BamHI restriction enzymes and ligated with the linearized vector, 
producing pBbovis-luc (Figure 9).  
 
Figure 9. Schematic diagram representing the development of the transient transfection plasmid Bbovis-
luc. (A) Schematic representation of pBrfp-bsd, the backbone for construction of pBbovis-luc.  represent the 
restriction sites of the enzymes used for construct development. ef-1α IG-B - flanking region of the ef-1α gene 
from B. bovis; RFP-bsd, gene coding a fusion protein comprising a Red fluorescent protein and Blasticidin-S 
Deaminase; 3’-rap-1, 3’ flanking region of the rhoptry associated protein-1 gene. (B) Firefly luciferase gene and 
3’ rap-1 were amplified by PCR with the represented primers and digested with BglII restriction enzyme. (C) PCR 
amplification of the firefly luciferase-3’rap-1 cassette was performed with the primers shown and the cassette was 
digested. (D) Ligation of the digested vector with firefly luciferase-3’rap-1 cassette to originate pBbovis-luc. 
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The pBef1αIG2, a plasmid carrying the B. ovata ef-1α IG-B region (Table 2) (kindly 
provided by professor Masahito Asada) was used as backbone for development of pBovata-luc. 
First, it was digested with EcoRV and EcoRI restriction enzymes and the resulting linearized 
vector was isolated and purified from a 0.8% low-melting point agarose gel as described in 
section 3.6. The luc gene was PCR amplified with PF-luc-EcoRV/ PR-luc-EcoRI and later 
digested with the same restriction enzymes to allow ligation of luc gene to the digested vector 
between B. ovata Ef-1-α IG-B sequence and 3′ rap-1a terminator region resulting in pBovata-
luc (Figure 10).  
 
Figure 10. Schematic diagram representing the development of the transient transfection plasmid Bovata-
luc. (A) Schematic representation of the plasmid used as backbone for construction of pBovata-luc.  represent 
the restriction sites of the enzymes used for construct development. ef-1α IG-B- flanking region of the ef-1α-B 
gene from B. ovata; 3’-rap-1, 3’ flanking region of the rhoptry associated protein-1 gene. (B) Firefly luciferase 
gene was amplified by PCR with the represented primers and digested with shown restriction enzymes. (C) 
Ligation of the digested vector with firefly luciferase originating pBovata-luc.  
A promoterless plasmid pBS luc was also developed to be used as negative control in 
assays to measure the luciferase activity. Briefly, pBovata-luc was digested with HindIII 
restriction enzyme to excise the promoter sequence. After vector isolation and purification from 
a 0,8% low-melting agarose gel as described in section 3.6, it was re-circularized by ligation 
(Figure 11).  
 
Figure 11. Schematic diagram representing the development of the promoterless plasmid, pBS-luc. (A) 
pBovata-luc was digested with represented restriction enzymes.  represents enzymes restriction sites. (B) pBS-
luc was generated by re-circularization. 
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3.10. Plasmid construct validation and preparation for transfection  
Plasmid constructs were transformed into E. coli JM109 competent cells and selection 
of the recombinant strains was performed by colony screening PCR using appropriate primer 
sets. Plasmids from colonies showing the expect PCR product were extracted and purified as 
described in section 3.6. Afterwards, enzymatic restriction was performed for construct 
confirmation and all the correct insertion was confirmed by Sanger sequencing at 
StabVida (Lisbon, Portugal) with the appropriate primers (Table 4). 
To obtain a higher amount of recombinant plasmids, a midiPrep was prepared using the 
Qiagen Plasmid Midi Kit (Qiagen) following manufacturers’ instructions. Plasmid DNA 
concentration was assessed as mentioned in section 3.6. to guarantee transfection of the desired 
plasmid DNA amount throughout transfection experiments.  
Table 4. Primers used for development of transfection constructs and to assess transfection efficiency. 
Primer Name Sequence (5’→3’) 
PCR product size 
(bp) 
Primers for transient transfection constructs 
PR-luc-BglII GCGAGATCTTTACAATTTGGACTTTCCG 
1653 
 
PF-luc-EcoRV GCCGATATCATGGAAGACGCCAAAAAC 
1653 
PR-luc-EcoRI CGCGAATTCTTACAATTTGGACTTTCCGC  
PF-bovis-rap-1-BglII GCCAGATCTGATGAGATGCGTTTATAATGG 
1294 
PR-bovis-rap-1-BamHI CGCGGATCCCCTACGAACGATATGTCAAAG 
PR-luc-seq. b CGCCGCCGTTGTTGTTTTGG  
PF-luc-seq. b CAGCCCATATCGTTTCATAGC  
M13F-pUC (-40) b GTTTTCCCAGTCACGAC  
Primers for development of a stable transfection construct 
PF-prom-ovata-SalI CTAGTCGACCACTCATTTAGATTGCGAC 724 
PR-prom-ovata-
HindIII 
CTGAAGCTTCTTGTTTAAGGTTTAACGATAG 
PF-5ef-ORF-XhoI GTTCTCGAGTTCAAGTACGGCCTGGGT 
483 
PR-5ef-ORF-SalI CTAGTCGACTTGCCCTTGTACCATGGC 
PF-3ef-ORF-NotI AGCGGCCGCGACCTTGGTCGAGGCCCTCGAC 
495 
PR-3ef-ORF-SacI GTCGAGCTCTTGTCCATACGGCAGGTGATCTCGTCG 
Primers for qPCR to evaluate transfection efficiency 
PF-BoSPD * TAATGACGCAGACCTGATGG 
141 
PR-BoSPD * GTTTGATCACCCTCGGAAAC 
PF-qPCR-luc GCTGGGCGTTAATCAGAGAG 
151 
PR-qPCR-luc GTGTTCGTCTTCGTCCCAGT 
Restriction enzyme sites are shown in bold. *Erster et al., 2016 161 
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3.11. Procedures for transfection  
B. ovis iRBCs with PPE approximately 6% were centrifuged at 1200 rpm for 10 min. 
The supernatant was discarded, and cell pellets were washed twice, first with PBS and then 
with cytomix buffer (120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 10 mM KH2PO4, 25 mM 
HEPES, pH 7.6, 2 mM EGTA, 5 mM MgCl2, 100 μg/ml bovine serum albumin, and 1 mM 
hypoxanthine), a protocol adapted from Asada et al 94. 
For transfection, two different protocols of iRBC preparation were conducted 
accordingly to the transfection kit in use. For the Basic Parasite Nucleofector™ Kit 2 (Lonza), 
20 µg of circular plasmid in elution buffer were mixed with Nucleofector™ Basic Solution for 
Parasites to a final volume of 100 µL, which was used to resuspend 100 µL of washed parasite-
iRBCs. For the Human T-cell Nucleofector™ Kit (Lonza), 20 µg or 50 µg of circular plasmid 
in elution buffer were mixed with cytomix buffer to make up a volume of 50 µL and added to 
50 µL of human T-cell buffer. Similarly, this mixture was used to resuspend 100 µL of washed 
parasite-iRBCs. The plasmid pmaxGFP™, provided in the Human T-cell Nucleofector™ Kit 
(Lonza), was used as positive control of transfection. Evaluation of successful transfection was 
performed by imaging B. ovis transiently expressing GFP under 400x original magnification of 
a Nikon eclipse 80i fluorescence microscope with Nikon DS-Ri1 camera (Nikon Europe, 
Amsterdam, Netherlands) and appropriate filter (GFP).    
Parasite-iRBCs were transfected with circular plasmids in a Nucleofector 2b Device 
with a v-024 program (Amaxa Biosystems, Cologne, Germany) and were immediately 
transferred to 1 ml culture containing 10 % ovine RBCs. Due to constrains related to buffer 
availability only one transfection was performed for each condition. Transfected parasites were 
cultured in 24-well plates as described previously in section 3.1.  
3.12. Chemiluminescence quantification to evaluate promoter activity and optimization 
of transfection process 
Assays to measure luciferase activity were performed to evaluate differences in 
transfection outcomes between two transfection kits, Basic Parasite Nucleofector™ Kit and 
Human T-cell Nucleofector™ Kit,  and between transfection with either 20 µg or 50 µg of 
plasmid DNA.  
After optimization of the transfection conditions by the previous evaluation, luciferase 
reporter assays were performed to quantify luciferase expression promoted by ef-1α-B 
intergenic regions from B. bovis and B. ovata (Figure 12).  
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Transient transfections were conducted by introducing 20 μg of each promoter plasmid 
expressing luc gene, pBbovis-luc and pBovata-luc and a promoterless plasmid for negative 
control, pBS-luc (detailed description in section 3.11). For evaluation of promoter activity at 
least three independent transfections of each plasmid construct were performed. Luciferase 
reporter assays were performed in triplicate at 24h, 48h and 72h after transfection using ONE-
Glo™ Luciferase Assay System (Promega). Following manufactures’ instructions, to 100 µL 
of transfected B. ovis culture, the same amount of ONE-Glo™ Luciferase Assay Reagent was 
added. To ensure complete cell lysis, this mixture was kept for 5 minutes at room temperature 
before reading luminescence. Luciferase assays were performed in triplicates in a 
Corning® Costar 96-well white plate (Corning Costar) and luminescence was measured for a 2 
sec. integration interval in a GloMax-Multi+ Detection System (Promega).  
3.13. Transfection efficiency by quantitative real-time PCR 
Transfection efficiency was evaluated through qPCR. DNA extraction was performed 
from 80 µL of transfected B. ovis culture (with pBbovis-luc, pBovata-luc and pBS-luc) 24h 
post-transfection, following the protocol described in section 3.5 (Figure 12).  
A qPCR was developed to assess the quantity of luc and B. ovis surface protein D 
(BoSPD) genes in the transfected B. ovis parasites using the sets of primers presented in table 
3,  following the minimum information for publication of qPCR experiments (MIQE) 
guidelines 162. The qPCRs were carried out in a CFX96 Touch™ Real-Time PCR Detection 
System (Bio-Rad, CA, USA) and the cycling conditions comprised an enzyme activation step 
at 95 ºC for 5 min followed by 35 cycles of denaturation at 95ºC for 10 s and 
annealing/extension at 51ºC for 15 s and 60 ºC for 15 s for luc and 54,5 ºC for 30 s for BoSPD. 
To confirm amplification specificity for luc and BoSPD, a melting curve was run (55 °C–95 °C; 
0.5 °C/s melt rates). Reactions were performed in triplicate to a final volume of 10 μL, with 
5 μL iTaq™ Universal SYBR® Green Supermix (Bio-Rad, CA, USA), for luc each primer at 
500 nM and for BoSPD each primer at 800 nM, 1 μL of DNA and nuclease-free water to achieve 
the final volume. Negative controls were prepared with no template.  
A gBlocks® Gene Fragment (Integrated DNA Technologies, Leuven, Belgium) was 
synthetized for both luc and BoSPD each with 151 and 141 bps, respectively. Standard curves 
were prepared for each gene with 10-fold serial dilutions of the synthetized gBlocks® Gene 
Fragment and obtained by plotting the threshold cycle (Cq) versus the natural log of 
concentration (ng/μl). These curves were used to determine qPCR reactions efficiency 
(analytical sensitivity) and for quantification of luc and BoSPD. Copy numbers of luc and 
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BoSPD genes were calculated based on the following formula, as done previously 163, assuming 
that BoSPD gene only has one copy per genome, where X represents the amount of amplicon 
(ng): 
 
Copy number =
X ng x 6,0221 x 1023 molecules/mols
Amplicon molecular weight x 1 x 109 ng/g
 
 
Transfection efficiency is presented as the ratio of plasmid/genome copies (luc/ BoSPD 
copies), as done elsewhere 90,95. 
 
 
Figure 12. Schematic representation of the methodologies used to evaluate activities of elongation factor-
1alpha intergenic region-B candidate promoters from Babesia bovis and Babesia ovata in Babesia ovis.  
3.14. Development of a stable transfection plasmid construct  
Brfp-bsd plasmid was digested with SalI and HindIII restriction enzymes to excise the 
pre-existing B. bovis ef-1α promoter region as described in section 3.6.  B. ovata ef-1α-B 
promoter region was amplified from pBef1αIG2 with primer set PF-prom-ovata-SalI/ PR-
prom-ovata-HindIII (Table 4) and ligated to the previously digested vector creating pBovata-
rfp-bsd. Confirmation of B. ovata ef-1α-B promoter region integration into the plasmid vector 
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was performed by a colony screening PCR, followed by Sanger sequencing with M13F-pUC 
(-40) primer at StabVida (Lisbon, Portugal).   
The construct was used for transient transfection using optimized procedures and RFP 
expression was validated by fluorescence microscopy. Briefly, images of B. ovis transiently 
expressing RFP were obtained under 100x original magnification of a Nikon eclipse 80i 
fluorescence microscope with Nikon DS-Ri1 camera (Nikon Europe, Amsterdam, Netherlands) 
and appropriate filter (Texas Red).   
PCR from previously extracted B. ovis gDNA (DNA extraction process in section 3.5) 
was used for generation of ef-1α flanking regions for stable transfection. The primer sets used 
were PF-5ef-ORF-XhoI and PR-5ef-ORF-SalI for B. ovis ef 3’ region (expected 495 bp 
amplicon); PF-3ef-ORF-NotI and PR-3ef-ORF-SacI for the 5’ region of B. ovis ef (expected 
483 bp amplicon). Sanger sequencing of the PCR products was performed at StabVida (Lisbon, 
Portugal).  
3.15. Statistical Analysis  
The luciferase activities and ratio of plasmid/ “genome copies” values were plotted 
using Microsoft Excel as the mean ± standard deviation, calculated from the triplicate samples. 
The one-way ANOVA analysis was used for data comparison (P<0.05) using GraphPad 
Prism6.  
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4. Results and Discussion 
4.1. Screening and identification of suitable regulatory regions in B. ovis genome 
 Brief note regarding B. ovis genome: one of the goals of the present study was the 
identification of regulatory regions in B. ovis genome, thus in line with the reasons described 
previously in the introduction section (1.3.2 and 1.3.4) the 5’ flanking region of the actin gene, 
the ef-1α and rap-1 locus, were chosen. However, recently we became aware that B. ovis Israeli 
strain genome had been sequenced but information is not public. Promptly the group 
responsible for this work, in the person of Doctor William Weir from University of Glasgow, 
was contacted for a collaborative effort. Therefore, in the following section all the strategies 
performed to amplify, sequence the aforementioned regions and the results will be discussed. 
When appropriate, results will be compared with information provided by Doctor William 
Weir. 
4.1.1. Isolation of the 5’ flanking region of the actin gene 
The first strategy was focused in PCR amplification of part of B. ovis actin gene using 
primers designed to amplify a 1246 bp fragment within B. bovis actin gene. A range of primer 
annealing temperatures between 59ºC and 55ºC was tested and it was observed that for all the 
temperatures a PCR product with approximately 1200 bp in size was originated, indicating the 
amplification of a product coincident in size to the expected in B. bovis (Figure 13). After 
sequencing the amplified product, we obtained a 952 nucleotides sequence. 
 
Figure 13. Amplification of part of Babesia ovis actin gene. Electrophoresis of the PCR products resultant of 
amplification of part of B. ovis actin gene in a 1.2% (vol/vol) agarose gel. From left to right: NZYDNA Ladder 
VI, gradient of annealing temperatures from 59ºC to 55ºC, PCR negative control (N).  
The alignment of the previously obtained sequence against B. ovis Israeli strain draft 
genome allowed to retrieve the complete B. ovis actin gene sequence (1131 bp) (Appendix I.1 
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and I.2). A BLAST search of the obtained sequence against available sequences in the NCBI 
Database from Babesiidae family was performed revealing the highest homology with B. bovis 
actin gene sequence (89% identity) (Table 5). A brief analysis showed a single continuous 1131 
bp ORF and comparison of the amino acid sequence against available sequences in the UniProt 
Database revealed 100% homology with B. sp. Xinjiang and B. bovis Actin protein showing 
that its highly conserved between Babesia spp. (Table 6).   
Table 5. Babesiidae annotated sequences producing significant alignments with Babesia ovis actin gene 
sequence. 
Description 
Maximum 
Score 
Total 
Score 
Percent 
Query 
Coverage 
E Value 
Maximum 
Percent 
Identity 
GenBank 
Accession Number 
Babesia bovis 
BBOV_I000300 
mRNA for actin, 
complete cds, clone: 
XBBk019120, strain: 
Texas 
1160 1160 99% 0 89% AK441690.1 
Babesia bigemina 
actin, putative partial 
mRNA 
1018 1018 99% 0 86% XM_012912903.1 
Babesia gibsoni actin 
mRNA, complete cds 
941 941 99% 0 85% XM_012912903.1 
 
Table 6. Babesiidae annotated protein sequences producing significant alignments with Babesia ovis actin 
translated sequence. 
 
Attempts to amplify and sequence the 5’ flanking region failed but it was possible to 
access this region after retrieving 1000 bp upstream B. ovis actin coding sequence (Appendix 
I.3) from B. ovis genome sequencing project. A discontiguous megablast was performed with 
this sequence and, for a query coverage of 40% (507 to 908 bp), it was found a 68% homology 
with the sequence correspondent to the promoter region of B. bovis strain actin gene (Appendix 
I.4). Analysis of the 5’ act was performed using the sequence obtained in the present study and 
three actin promoter sequences from B. bovis, B. ovata and B. gibsoni (GenBank accession 
numbers: MF598086, LC101765 and MF598081). Using MEME bioinformatic tool, it was 
possible to detect 3 motif sequences almost co-localized between sequences from B. ovis and 
B. bovis (GCCCCAGCG, CACATGTGCT and GGCACCGCTG p<0.0001). The TSS initiator-
 
Protein name 
 
Score E Value Identity Accession Number 
Actin (Babesia sp. 
Xinjiang) 
1958 0.0 100.0% A0A1X1BPP4 
Actin (Babesia bovis) 
1958 0.0 100.0% A7AX51 
Actin, putative 
(Babesia bigemina) 
1940 0.0 98.7% A0A061D645 
Actin (Babesia gibsoni) 1915 0.0 96.5% Q5EF72 
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like motif, TYAYWWW, was searched using FIMO program and, for B. bovis this motif was 
found located 152 bp before the actin coding sequence, which is the median length described 
between the TSSs to the coding sequence 5’ end (p<0.0001) for this species 113. This motif is 
also present in T. parva genome, usually, 3 bp upstream of TSSs, but seems that other motifs 
might have similar functions 120. This consensus sequence was found in B. ovis but located in a 
region that apparently should not have a role as TSS 123,164.  
Transfection using actin promoter was achieved for B. ovata, B. bovis and B. gibsoni 
with 2300 bp, 1800 bp and 1455 bp, respectively, of the 5’ flanking region of the gene 7,94,100 
suggesting that essential transcriptional factors, bind in the most proximal 5´ region. Though, 
cis-regulatory elements play a significant role in promoter activity, imposing a positive or 
negative effect as it was described for T. gondii 119,165. Some recently reported results have 
shown that B. gibsoni 5’act was able to drive more expression of the reporter gene than the 
homologous promoter region in B. bovis 127. Since no homology exists between the two 
sequences, the presence of motifs in B. gibsoni 5’act lacking in B. bovis 5’act, for which B. 
bovis transcriptional factors had more affinity, can be suggested 112. Therefore, having in mind, 
that almost half of the B. ovis 5’act region has a 68% homology with B. bovis, it would be 
interesting to conduct a transient transfection in both parasites to check promoter activity of this 
most “conserved” portion in comparison with the all B. ovis 5’act sequence available.  
Transfection studies in apicomplexan parasites have been used as a proof of concept for 
the functionality of several promoter regions and even to identify interspecies activity of some 
them, however the application of such genetic manipulation methods for the identification of 
key motifs that define the promoter sequences are urgently required 2.    
4.1.2. Exploring elongation factor 1-alpha locus 
 The ef-1α locus organization in B. bovis and B. bigemina comprises two identical ef-1α 
genes, designated ef-1α-A and ef-1α-B, arranged in a head to head orientation, separated by an 
intergenic region 91,95. Two strategies were developed, both based in the design of primers 
hybridizing in B. bovis ef-1α-B gene in sites showing the lowest nucleotide divergence between 
three Babesia species.  
4.1.2.1 A structure similarity-based strategy 
The first strategy used to amplify B. ovis ef-1α IG region assumed an identical structure 
between B. ovis and B. bovis ef-1α locus. Therefore, it was expected that the designed 
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oligonucleotides would amplify fragments containing the intergenic region, with approximately 
1500 bp, 1800 bp and 2100 bp in size (Figure 14).    
 
Figure 14. Expected amplicon sizes for PCR with primers PR-Ef-ORF-B-RV1 and PR-Ef-ORF-B-RV3. The 
amplicon size estimated assumes an identical structure between B. ovis and B. bovis ef-1α locus. Grey arrows 
represent primers hypothetical hybridization sites in ef-1α-A gene. Expected orientation of the open reading frames 
(ORF) is shown with black arrows (not for scale).   
 PCR experiments were carried out using a DNA polymerase with proofreading activity, 
and, of several B. bovis PCR products, amplicons with approximately 1000 bp, 1800 bp and 
2000 bp were originated, which coincided in size to the expected (Figure 14 and Figure 15A, 
lane Bb), validating the present approach. In B. ovis, one of the obtained amplicons, with 
approximately 1500 bp (Figure 15A, lane Bo), was subjected to a re-amplification (Figure 
15B) and selected for isolation (Figure 15C) due to its relative size proximity to the 1800 bp 
fragment amplified in B. bovis.  
 
Figure 15. Amplification and isolation of a Babesia ovis 1500 base pairs (bp) size fragment. Electrophoresis 
of (A) the PCR products resultant of amplification with primers PR-Ef-ORF-B-RV1 and PR-Ef-ORF-B-RV3 
having B. ovis (Bo) and B. bovis (Bb) gDNA as template, (B) re-amplification of the previously obtained PCR 
product and (C) isolation and purification of the 1500 bp fragment in a 0.8% (vol/vol) agarose gel. Products 
approximate size was determined by comparison with GeneRuler 1 kb DNA Ladder shown in the left.  
The previously obtained 1500 bp amplicon was cloned into the pCRTM-Blunt I-TOPO 
originating TOPO-RV1RV3 and, after validating the presence of the fragment, it was sent to 
Sanger sequencing. A BLAST optimized to search for dissimilar sequences (discontiguous 
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megablast) was conducted for the sequences obtained (two products with 692 bp and 794 bp) 
(Appendix II.1), revealing, for the highest coverage of the submitted sequences, a 68% 
nucleotide sequence identity with a B. bovis coding sequence for protein kinase domain 
containing protein (Table 7). 
Table 7. Babesiidae annotated sequences producing significant alignments with the cloned Babesia ovis 1500 
base pairs in size sequence. 
Description 
Maximum 
Score 
Total 
Score 
Percent 
Query 
Coverage 
Expect 
Value 
Maximum 
Percent 
Identity 
GenBank 
Accession Number 
Babesia bovis 
BBOV_III003600 
mRNA for protein 
kinase domain 
containing protein, 
complete cds, clone: 
XBBk019034, strain: 
Texas 
230 460 84% 1-55 68% AK441676.1 
Babesia bovis protein 
kinase domain 
containing protein 
(BBOV_III003600) 
mRNA, complete cds 
228 457 84% 5-55 68% XM_001611442.1 
Babesia bigemina 
protein kinase domain 
containing protein, 
putative partial mRNA 
72.5 145 14% 8-8 75% XM_012913984.1 
 
 PCR experiments were conducted using a Taq II DNA polymerase and for the same 
annealing temperature tested before (54.4 ºC), PCR products with a size closer to 2000 bp were 
observed. Lowering the annealing temperature until 49.5 ºC favored the amplification of these 
products whose size were closer to the 1813 bp and 2118 bp as obtained in B. bovis (Figure 
16). Sequencing of amplicons failed. Also, attempts were performed to replicate this result 
using a DNA polymerase with a proofreading activity without success.  
 
Figure 16. Attempts for Babesia ovis elongation factor 1-alpha Intergenic region amplification. 
Electrophoresis of the PCR products resultant of amplification with primers PR-Ef-ORF-B-RV1 and PR-Ef-ORF-
B-RV3 having B. ovis gDNA as template in a 1.2% (vol/vol) agarose gel. From left to right: NZYDNA Ladder 
VIII, gradient of annealing temperatures from 56ºC to 49.5 ºC, PCR negative control (N). 
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The failure to amplify B. ovis ef-1α IG region could be related with the lack of specificity 
of the designed primers for the intended hybridization sites in B. ovis. However, the number of 
mismatches or even a single mismatch at the primer 3’ end, that affect PCR more dramatically 
than at other positions, 166,167 should only result in a reduction of amplification efficiency, still 
allowing amplification to occur. Using the of B. ovis ef-1α sequence (Appendix III.2) retrieved 
from the B. ovis genome this hypothesis was tested with PR-Ef-ORF-B-RV1 presenting a single 
nucleotide mismatch (3 bps from the 3’ end) and PR-Ef-ORF-B-RV3 having two nucleotides 
diverging from the template sequence, one located at 7 bps from the 5´end and other at 2 bp 
from the 3´end.  
Overall, these results may point to a different locus organization, contrary to other 
Babesia spp. This locus structure is identical between B. bovis, B. bigemina and B. ovata with 
synteny among the two ef-1α genes reported to be conserved among B. bigemina, B. bovis and 
Plasmodium parasites 91,95. Therefore, more studies should be conducted to understand B. ovis 
ef-1α locus structure. 
4.1.2.2 A PCR-mediated genome walking method 
Since the previous strategy failed to amplify the fragment of interest, a second approach, 
consisting in an adapted PCR-mediated genome walking method was performed. Here, PCR 
was carried out with a sequence-specific primer, plus non-specific primers hybridizing in the 
unknown region 158,168,169170. Hence, there was the need to first amplify and sequence the region 
adjacent to the unknown region, the ef-1α gene.  
Based on the previous used alignment, two primers were designed to amplify part of B. 
ovis ef-1α gene, correspondent to an amplicon of approximately 947 bp in size. One amplicon 
was obtained with the expected size (Figure 17).  
 
Figure 17. Amplification of part of Babesia ovis elongation factor-1alpha gene. Electrophoresis of the PCR 
product resultant of amplification of part of B. ovis ef-1α gene in a 1.2% (vol/vol) agarose gel. From left to right: 
NZYDNA Ladder VIII, PCR negative control (N). 
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The 940 bp product was sequenced and a BLAST search revealed a high nucleotide 
sequence homology with B. ovata and B. bigemina (92%). Alignment of the partial ef-1α gene 
obtained with the B. ovis draft genome was also performed and complete B. ovis ef-1α gene 
sequence is now described (Appendix III.1 and III.2) (Table 8).  
Table 8. Babesiidae sequences producing significant alignments with Babesia ovis elongation factor-1alpha 
gene sequence.  
Description 
Maximum 
Score 
Percent 
Query 
Coverage 
Expect 
Value 
Maximum 
Percent Identity 
Accession Number 
Babesia ovata strain 
Miyake transcript 
1948 100% 0.0 92% BOVATA_017780-t37_1* 
Babesia bigemina 
strain Puerto Rico 
elongation factor 1 
alpha A and elongation 
factor 1 alpha B genes, 
complete cds 
1946 100% 0.0 92% XM_012911267.1 
Babesia divergens 
genome assembly 
454hybrid_PBjelly, 
scaffold Contig2 
1853 100% 0.0 90% LK934712.1 
Babesia bovis 
elongation factor 1-
alpha 
(BBOV_IV010630) 
mRNA, complete cds 
1817 100% 0.0 90% XM_001610934.1 
Babesia microti strain 
R1 elongation factor 
EF-1 alpha subunit 
820 100% 0.0 74% BMR1_03g03490-t32_1* 
*Accession number correspondent to transcript identification (Gene ID) in EuPathDB genomic resources database 
After designing a reverse primer hybridizing in B. ovis ef-1α gene sequenced region 
(PR-Ef-ovis-specific) and two non-specific primers targeting the least divergent sites between 
B. bovis and B. bigemina ef-1α-B 5’ flanking region (PF-Ef-IG1 and PR-Ef-IG3), PCR 
experiments were conducted. PCR with PF-Ef-IG1/ PR-Ef-ovis-specific and PR-Ef-IG3/ PR-
Ef-ovis-specific were expected to result in amplicons with approximately 1200 bp and 900 bp, 
respectively (Figure 18).  
 
Figure 18. Expected amplicon sizes for PCR with primers PR-Ef-IG1/ PR-Ef-ovis-specific and PR-Ef-IG3/ 
PR-Ef-ovis-specific. The amplicon size estimated assumes an identical structure between B. ovis and B. bovis ef-
1α locus. Hybridization sites of primers are shown (not for scale). Expected orientation of the open reading frame 
(ORF) is shown with a black arrow. 
Among several B. ovis PCR products, amplicons with approximately 1400 bp were 
obtained with PF-Ef-IG1/ PR-Ef-ovis-specific (Figure 19A). Also, using the second primer 
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set, amplicons of similar size were amplified, and lowest annealing temperatures (43.9 and 
41.4ºC) resulted in the amplification of DNA fragments with 900 bp (Figure 19B).  
 
Figure 19. Attempts for amplification of Babesia ovis elongation factor-1α 5’ flanking region. Electrophoresis 
of the PCR products resultant of (A) amplification with PF-Ef-IG1/ PR-Ef-ovis-specific and (B) amplification 
with PF-Ef-IG3/ PR-Ef-ovis-specific in a 1.2% (vol/vol) agarose gel. From left to right: NZYDNA Ladder VII, 
gradient of annealing temperatures from 61ºC to 41.4 ºC, PCR negative control (N). 
The PCR products obtained with 1400 bp and 900 bp in size were isolated, purified and 
sent to sequencing with the PR-Ef-ovis-specific however, only a 332 bp sequence was retrieved 
(Appendix IV.1), which did not align with the B. ovis ef-1α gene sequence. Considering that 
the PR-Ef-ovis-specific was designed to hybridize 185 bp downstream ef-1α gene start codon, 
the absence of this “anchor” sequence indicated that no B. ovis ef-1α 5’ flanking region was 
amplified. Moreover, a discontiguous megablast was performed for the obtained sequence and 
no homology was found against Babesiidae sequences (Appendix IV.2). 
PCR experiments with PF-Ef-IG3/ PR-Ef-ovis-specific were conducted at lower 
annealing temperatures (40ºC to 36 ºC) increasing the amount of the 900 bp PCR product 
(Figure 20). After isolation and purification, fragment was sent for sequencing in both 5´and 
3´direction. Alignment of the sequences demonstrated that a single continuous 745-nucleotide 
fragment had been sequenced (Appendix V.1).  
 
Figure 20. Attempts for amplification of Babesia ovis elongation factor-1alpha 5’ flanking region with 
annealing temperatures between 36ºC and 40ºC. Electrophoresis of the PCR products resultant of amplification 
with PF-Ef-IG3/ PR-Ef-ovis-specific in a 1.2% (vol/vol) agarose gel. From left to right: NZYDNA Ladder VII, 
gradient of annealing temperatures from 40 ºC to 36 ºC, negative control (N). 
40 
 
Analysis showed that again no B. ovis ef-1α gene sequence was present in the amplicon. 
A discontiguous megablast was also conducted and demonstrated homology with  B. bovis and 
B. bigemina hypothetical protein partial mRNA sequence. Herein, only alignments that have a 
coverage of the query sequence above 30% are shown (Table 9).  
Table 9. Babesiidae sequences producing significant alignments with the Babesia ovis obtained sequences 
from the genome walking PCR method. 
Description 
Maximum 
Score 
Total 
Score 
Percent 
Query 
Coverage 
Expect 
Value 
Maximum 
Percent 
Identity 
GenBank 
Accession Number 
Babesia bovis 
BBOV_IV001750 
mRNA for hypothetical 
protein, complete cds, 
clone: XBBk027088, 
strain: Texas 
88.7 88.7 42% 4-13 68% AK442121.1 
Babesia bigemina 
genome assembly 
Bbig001, chromosome 
: V 
82.4 82.4 56% 2-11 66% LK391711.1 
Babesia bigemina 
hypothetical protein, 
conserved partial 
mRNA 
77.0 77.0 55% 7-10 65% XM_012914811.1 
Babesia divergens 
genome assembly 
454hybrid_PBjelly, 
scaffold Contig3 
68.0 68.0 44% 3-7 66% LK934713.1 
 
Additionally, the amplified 745 bp sequence blasted against sequences available in the 
EuPathDB genomic resources database. Homology with sequences from B. ovata strain 
Miyake, B. bigemina strain BOND and B. bovis T2Bo were found (different sequence IDs seen 
in table 10) which did not co-localize with the ef-1α locus in these species 171.   
Table 10. Babesiidae sequences producing significant alignments with the Babesia ovis obtained sequences 
from the genome walking PCR method and their genomic location. 
Organism 
Sequence ID which contains 
the region of alignment 
Score E-value 
Sequence ID which 
contains the ef-1α locus 
Babesia ovata 
strain Miyake 
 
BDSA01000005 
 
78.8 3-12 BDSA01000002 
Babesia bigemina 
strain BOND 
 
LK391711 
 
 
64.4 
 
6-8 
LK391707 
Babesia bovis 
T2Bo 
 
AAXT01000004 
 
48.2 
0.004 AAXT01000002 
 
More studies need to be performed to clarify these results. Contrasting with the 
nucleotide sequence homology of ef-1α coding sequence between Babesia spp. (Table 8) and 
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other Apicomplexa, the ef-1α IG region is not conserved between species and between B. bovis 
and B. bigemina the IG sequence was considered unrelated 91,95.  
The alignment of B. ovis ef-1α gene produced only one hit against B. ovis genome 
sequence which could indicate the presence of only one copy. However, only 155 bp upstream 
the gene were retrieved, indicating a possible sequencing gap in this region (Appendix V.II).  
4.1.2.1.1 Analysis of Babesia ovis Elongation factor 1-alpha  
A brief analysis to B. ovis ef-1α ORF shows that encodes a protein of 448 amino acids 
with a predicted molecular weight of 49.31 Da, equal in size with homologues from B. bovis, 
B. bigemina and B. sp. Xinjiang, having the highest amino acid similarity with the latter (96.7%) 
(Table 11). Moreover, amino acid sequence analysis reveals the conservation of all putative 
guanosine 50-triphosphate (GTP) binding regions (Figure 21), essential for the GTP-dependent 
binding of aminoacyl-tRNA to ribosomes during protein biosynthesis, also reported to 
conserved in T. parva and P. falciparum 91,95,172,173. This suggests that this protein probably has 
an identical function between these apicomplexan parasites, being a key component of the 
protein translation mechanism. Moreover, it also indicates that to consider B. ovis ef-1α gene 
as a target for genome integration of a stable transfection system the presence of the two copies 
is essential to ensure parasite survival.  
Table 11. Babesiidae Elongation factor 1-alpha protein sequences producing significant alignments  with 
Babesia ovis.  
Organism Score E value Identity 
UniProt Accession 
number 
Babesia sp. Xinjiang 2268 0.0 96.7% A0A1X1BH95 
Babesia ovata 2250 0.0 95.3% A0A2H6KBC5 
Babesia bigemina 2250 0.0 95.3% A0A061D9W5 
Babesia bovis 2245 0.0 95.5% Q2LEY6 
Babesia microti (strain RI) 2026 0.0 85.9% A0A0K3ARN2 
 
 
B.ovis        MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESTDMGKGSFKYAWVL 60 
B.sp.Xinjiang MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESTDMGKGSFKYAWVL 60 
B.ovata       MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESTDMGKGSFKYAWVL 60 
B.bigemina    MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESTDMGKGSFKYAWVL 60 
B.bovis       MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKESTDMGKGSFKYAWVL 60 
B.microti     MPKEKTHINLVVIGHVDSGKSTTTGHLIYKLGGIDKRTIEKFEKDSSEMGKSSFKYAWVL 60 
              ********************************************:*::***.******** 
 
B.ovis        DKLKSERERGITIDITLWKFETSKYYYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAEA 120 
B.sp.Xinjiang DKLKSERERGITIDITLWKFETAKYYYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAEA 120 
B.ovata       DKLKSERERGITIDITLWKFETGKYYYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAEA 120 
B.bigemina    DKLKSERERGITIDITLWKFETGKYYYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAEA 120 
B.bovis       DKLKSERERGITIDITLWKFETTKYYYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAEA 120 
B.microti     DKLKSERERGITIDITLWKFETQKYEYTVIDAPGHRDFIKNMITGTSQADVAMLVVPAES 120 
              ********************** ** *********************************: 
GTP BS1 
GTP BS2 
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B.ovis        GGFEAAFSKEGQTREHALLAFTLGVRQIICAINKMDKCDYKEDRYSEIQKEVQGYLKKVG 180 
B.sp.Xinjiang GGFEAAFSKEGQTREHALLAFTLGVKQIICAINKMDKCDYKEDRYSEIQKEVQGYLKKVG 180 
B.ovata       GGFEAAFSKEGQTREHALLAFTLGVKQIICAINKMDKCDYKEDRYSEIQKEVQGYLKKVG 180 
B.bigemina    GGFEAAFSKEGQTREHALLAFTLGVKQIICAINKMDKCDYKEDRYSEIQKEVQGYLKKVG 180 
B.bovis       GGFEAAFSKEGQTREHALLAFTLGVKQIICAINKMDKCDYKEDRYSEIQKEVQGYLKKVG 180 
B.microti     GGFEAAFSKEGQTREHALLAFTLGVKQMIVAINKMDSCQYKEDRYMEIFKEVQQYLKKVG 180 
              *************************:*:* ******.*:****** ** **** ****** 
 
B.ovis        YNTDKVPFVAISGFMGDNMVERSTNMPWYKGKTLVEALDMMEPPKRPVDKPLRLPIQGVY 240 
B.sp.Xinjiang YNIEKVPFVAISGFMGDNMVERSTNMPWYKGKTLVEALDMMEPPKRPIDKPLRLPLQGVY 240 
B.ovata       YNIEKVPFVAISGFMGDNMVERSTNMPWYKGKTLVEALDMMEPPKRPVDKPLRLPLQGVY 240 
B.bigemina    YNIEKVPFVAISGFMGDNMVERSTNMPWYKGKTLVEALDMMEPPKRPVDKPLRLPLQGVY 240 
B.bovis       YNIEKVPFVAISGFMGDNMVERSTNMPWYKGKTLVEALDQMEPPKRPVDKPLRLPLQGVY 240 
B.microti     YKVESVPFVAISGFHGDNMVEKSTNMPWYKGKTLVEALDQMEPPKRPVEKPLRLPLQSVY 240 
              *: :.********* ******:***************** *******::******:*.** 
 
B.ovis        KIGGIGTVPVGRVETGQLKAGMVLTFAPNPITTECKSVEMHHEVVEVAYPGDNVGFNVKN 300 
B.sp.Xinjiang KIGGIGTVPVGRVETGQLKAGMVLTFAPNPITTECKSVEMHHEVVEVASPGDNVGFNVKN 300 
B.ovata       KIGGIGTVPVGRVETGQLKAGMVLTFAPNPITTECKSVEMHHEVIDVASPGDNVGFNVKN 300 
B.bigemina    KIGGIGTVPVGRVETGQLKAGMVLTFAPNPITTECKSVEMHHEVIDVASPGDNVGFNVKN 300 
B.bovis       KIGGIGTVPVGRVETGMLKAGMILTFAPNPITTECKSVEMHHETVEVAYPGDNVGFNVKN 300 
B.microti     KIGGIGTVPVGRVETGQLKAGMIITFAPTGLTTECKSVEMHHEVVEVASPGDNVGFNVKN 300 
              **************** *****::****. :************.::** *********** 
 
B.ovis        VSTSDIRSGHVASDSKNDPAKAAVSFSAQVIVLNHPGNIKAGYTPVVDCHTAHVSCKFDE 360 
B.sp.Xinjiang VSTSDIRSGHVASDSKNDPAKAAVSFSAQVIVLNHPGTIKAGYCPVVDCHTAHVSCKFDE 360 
B.ovata       VSTSDIRTGHVASDSKNDPAKAAVSFTAQVIILNHPGTIKAGYSPVVDCHTAHISCKFDE 360 
B.bigemina    VSTSDIRTGHVASDSKNDPAKAAVSFTAQVIILNHPGTIKAGYSPVVDCHTAHISCKFDE 360 
B.bovis       VSTSDIRSGHVASDSKNDPAKAAVSFTAQVIVLNHPGTIKAGYCPVVDCHTAHISCKFEE 360 
B.microti     VSVKDIKRGNVASDSKNDPAKEATSFSAQVIVLNHPGTIKAGYSPVVDCHTAHIACKFES 360 
              **..**: *:*********** *.**:****:*****.***** *********::***:. 
 
B.ovis        ITCRMDKRTGKSLEENPKSIKNGDAAIVTLKPCKPMVVESFTEYAPLGRFAVRDMKQTVA 420 
B.sp.Xinjiang LTSRMDKRTGKALEENPKTIKNGDAAMVTLKPCKPMVVESFTEYAPLGRFAVRDMKQTVA 420 
B.ovata       ITSRMDKRTGKALEENPKTIKNGDAAMVVLKPCKPMVVEAFTEYAPLGRFAVRDMKQTVA 420 
B.bigemina    ITSRMDKRTGKALEENPKTIKNGDAAMVVLKPCKPMVVEAFTEYAPLGRFAVRDMKQTVA 420 
B.bovis       ITSRMDKRTGKSLEENPKTIKNGDAAMVVLKPMKPMVVESFTEYAPLGRFAVRDMKQTVA 420 
B.microti     LDTRIDKRTGKTLEENPKTIKNGDAAMVTMKPNKPMVVETFTDYAPLGRFAVRDMRQTVA 420 
              :  *:******:******:*******:*.:** ******:**:************:**** 
 
B.ovis        VGVIKSVEKKEPGSSAKITKSAQKAAKK 448 
B.sp.Xinjiang VGVIKSVEKKEPGSSAKVTKSAQKAAKK 448 
B.ovata       VGVIKSVEKKEPGSSAKITKSAQKASKK 448 
B.bigemina    VGVIKSVEKKEPGSSAKITKSAQKASKK 448 
B.bovis       VGVIKSVEKKEPGSSAKVTKSAQKAAKK 448 
B.microti     VGIIKAVEKKDPSSA-KVTKSAVKAGKK 447 
              **:**:****:*.*: *:**** **.** 
 
Figure 21. Alignment of Elongation factor 1-alpha protein sequences from Babesia species. 
Comparison between Ef-1α protein sequences from B. ovis, B. sp. Xinjiang (A0A1X1BH95), B. ovata 
(A0A2H6KBC5), B. bigemina (A0A061D9W5), B. bovis (Q2LEY6) and B. microti (A0A0K3ARN2). 
Three conserved EF-1a regions with known guanosine 50-triphosphate (GTP)-binding site function 
(GTP BS 1, 2 and 3) are shown in bold.  
4.1.3 Exploring the rhoptry associated protein 1 locus  
The approach to understand B. ovis rap-1 locus consisted in the design of a forward 
primer hybridizing in a region found dissimilar between the available rap-1 gene copies 
sequences and a reverse primer hybridizing in the 3’end of the last known rap-1 gene copy. 
GTP BS3 
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PCR led to the amplification of a PCR product with approximately 2000 bp in size  (Figure 
22). The 2000 bp amplicon was cloned into the pCRTM-Blunt I-TOPO and, after validating the 
presence of the fragment, it was sent to Sanger sequencing. From the 2000-nucleotide amplicon 
only 953 bp were sequenced. All the sequenced product aligned completely with the sequence 
already available (GenBank accession number: M91169) (Appendix VI.1).   
 
Figure 22. Amplification of Babesia ovis rhoptry associated protein 1 gene and 3' end. Agarose gel 
electrophoresis at 0.8 % (vol/vol) of the PCR product resultant of amplification with Rap1α-Dissimilar-FW and 
Rap1-3-RV. DNA marker: NZYDNA Ladder VII. 
Recently it was possible to align this obtained sequence against B. ovis Israeli strain, 
retrieving a sequence that might correspond to the rap 1 locus sequence, however further studies 
are required to elucidate de locus organization. The intergenic region has already been 
sequenced which will be useful for the development of constructs with B. ovis autologous 
regulatory regions.   
 
4.2. Transient plasmids construction 
Being aware of the recognized inter-species activity of the ef-1α promoters among 
Babesia spp., pBbovis-luc and pBovata-luc were constructed with B. bovis and B. ovata ef-1α 
IG-B driving expression of a reporter protein luciferase, respectively. In addition, a 
promoterless plasmid was also developed to use as negative control in assays to measure the 
luciferase activity.  
4.2.1. Development of plasmid with Babesia bovis elongation factor-1alpha intergenic region-
B driving expression of a reporter luciferase 
The pBrfp-bsd (Table 2) was used as backbone for development of plasmid pBbovis-
luc. First, the plasmid was restricted with EcoRV and BamHI removing the RFP-BSD and 3’rap 
regions. The remaining plasmid, a fragment of 3671 bp containing the B. bovis ef-1α IG-B 
sequence was extracted from the gel. In a second step a luc-3’rap-1 cassette was constructed to 
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replace the previously excised terminator region and insert the desired reporter luciferase 
sequence. For this, the luc gene was amplified from pLVX-TetOne™-Puro-Luc (Table 2) and 
the 3’rap region from pBrfp-bsd by PCR, originating products with approximately 1600 bp and 
1300 bp, very near to the expected 1653 bp and 1295 bp, respectively (Figure 23).   
           
Figure 23. Digestion of plasmid Brfp-bsd and amplification of firefly luciferase (luc) gene and rhoptry 
associated protein-1 terminator region (3’rap-1). Electrophoresis of the (A) products of plasmid Brfp-bsd 
restriction digestion with EcoRV and BamHI restriction enzymes, (B) PCR product resultant of luc gene 
amplification with pLVX-TetOne™-Puro-Luc as template and (C) PCR product resultant of 3’ rap-1 amplification 
having pBrfp-bsd as template in a 0.8 % (vol/vol) agarose gel. Products approximate size was determined by 
comparison with GeneRuler 1 kb DNA Ladder (Thermo Fisher Scientific).  
The presence of the BglII restriction site at the 3’ end of  luc and 5’ end of rap 3’ allowed 
the ligation of the two fragments after digestion of the purified PCR products with BglII. To 
ensure the success of the ligation, the reaction was performed using 1:1, 2:2, 3:2 and 4:3 for luc 
: rap 3’ molar ratios. After heat inactivation of the T4 DNA ligase, PCR amplification of the 
luc-3’rap-1 cassette was performed. An agarose gel electrophoresis was performed showing no 
noteworthy differences in the quantity of PCR product resultant from amplification with 
different ligation reactions (Figure 24).  
              
Figure 24. Amplification of luciferase-rhoptry associated protein 3’ cassette. Electrophoresis of the PCR 
products resultant from luc-3’rap-1 cassette amplification having different ligation reactions as template (1:1, 2:2, 
3:2, 4:3) in a 0.8 % (vol/vol) agarose gel. Products approximate size was determined by comparison with 
GeneRuler 1 kb DNA Ladder (Thermo Fisher Scientific). 
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The luc-3’rap-1 cassette obtained was then digested with EcoRV and BamHI restriction 
enzymes and ligated with the 3600 bp plasmid fragment obtained above (Figure 23A), 
correspondent to the isolated vector. In parallel, another ligation experiment was conducted: 
the ligation of luc-3’rap-1 with all the digestion products, without isolation of the vector.   
Ligation reaction proportions of 1:1 and 0.5:1 (vector: fragment) were performed and 
transformed in E. coli JM109. More colonies appeared after transformation with ligation 
reactions containing the isolated vector and the ratio 0.5:1 was more efficient (Figure 25).  
 
Figure 25. Escherichia coli JM109 colonies after transformation with different ligation reactions to originate 
pBbovis-luc. From left to right, ligation reaction with: isolated vector at a 1:1 (vector: fragment) ratio, non-isolated 
vector at a 1:1 ratio, isolated vector at 0.5:1 ratio and non-isolated vector at 0.5:1 ratio. 
 After one round of replication, a colony screening PCR was performed using primers 
targeting luc-3’rap-1 cassette amplification and two colonies were shown to be positive for the 
presence of the fragment, one correspondent to passage of E. coli JM109 transformed with a 
ligation reaction containing the isolated vector (1:1 ratio) and the other with the non-isolated 
vector (0.5:1 ratio). After a second replication round of the positive clones followed by colony 
screening PCR, only 3 positive clones for the luc-3’rap-1 fragment were obtained, of which 
DNA was extracted and analysed by enzymatic restriction. Cleavage with EcoRV and BamHI 
produced two fragments, one with approximately 3500 bp, corresponding to the vector (3671 
bp size), and a fragment between 2500 and 3000 bp that should correspond to the luc-3’rap-1 
cassette. Incomplete digestion of some clones was observed (clones 3a and 3b), whereas a 
unique fragment was produced with approximately 6000 bp correspondent to the linearized 
vector (Figure 26).  
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Figure 26. Colony screening PCR in transformed Escherichia coli JM109 with expected pBbovis-luc 
targeting luc-3’rap-1 cassette amplification. From left to right: Electrophoresis of the PCR products resultant 
from a colony PCR to a passage from E. coli JM109 transformed with the following ligation reactions: isolated 
vector at a 1:1 (vector: fragment) ratio (1), non-isolated vector at a 1:1 ratio (2), isolated vector at 0.5:1 ratio (3) 
and non-isolated vector at 0.5:1 ratio (4) and to passages from the previously mentioned (2a→3d) in a 0.8 % 
(vol/vol) agarose gel. N: Negative control. PCR product approximate size and the was determined by comparison 
with GeneRuler 1 kb DNA Ladder.  
 Confirmation of correct fragment insertion was performed by sequencing clone 3a with 
primers PR-luc-seq., PF-luc-seq and M13F-pUC (-40), and after several alignments it was 
detected that luc gene sequence differed from the template sequence used to design the primer 
(Appendix VII.1). After accessing the sequence of the luc gene present in pLVX-TetOne™-
Puro-Luc, it was found that the sequence used to design the primers was different. Given the 
hybridization site of the primers designed, the luc gene present in pBrfp-bsd was probably 
truncated. Promptly, a new reverse primer was designed to appropriately amplify luc gene and 
a correct pBrfp-bsd was constructed as it follows.  
 Clone 3a was digested with BglII and EcoRV restriction enzymes and luc gene was 
excised with the same enzymes. Ligation reactions were performed with vector: fragment ratios 
of 1:3, 1:5 and 0.5:3 and PCR colony screening targeting luc gene was performed throughout 
two replication rounds of the positive clones. Restriction digestion of clones 6, 8, 9 and 12 was 
performed with BglII and HindIII restriction enzymes which should produce 3 fragments, one 
with approximately 800 bp corresponding to the promoter region, other with approximately 
1600 bp correspondent to luc gene and a third fragment correspondent to the remaining vector 
(≈3600 bp). The absence of this pattern was probably related with an incomplete digestion and, 
PCR aiming amplification of luc gene was performed to the same clones, resulting in the 
amplification of a fragment with the expected size in clone 9 (Figure 27). 
N 
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Figure 27. Development and validation of plasmid with Babesia bovis elongation factor-1alpha Intergenic 
region-B driving expression of firefly luciferase gene (pBbovis-luc). Electrophoresis of the (A) PCR product 
resultant of luc gene amplification with pLVX-TetOne™-Puro-Luc as template, (B) products of clone3a digestion 
with EcoRV and BamHI restriction enzymes, (C) PCR products resultant from a colony PCR targeting luc gene 
(1→12), (D) restriction digestion of clones 6, 8, 9 and 12 with HindIII and BglII restriction enzymes and (E) PCR 
products resultant of luc gene amplification with clones 6, 8, 9 and 12 as template, in a 0.8 % (vol/vol) agarose 
gel. N: Negative control. Products approximate size was determined by comparison with GeneRuler 1 kb DNA 
Ladder.   
 Correct integration of luc gene was validated by sequencing clone 9 (Appendix VIII).  
4.2.2. Development of plasmid with Babesia ovata elongation factor-1alpha intergenic region-
B driving expression of a reporter luciferase 
The pBef1αIG2 was used as backbone for the development of pBovata-luc. Briefly, the 
pre-existing reporter Renilla Luciferase, was excised from the plasmid and replaced by luc 
gene. To achieve this, pBef1αIG2 was digested with the EcoRV and EcoRI restriction enzymes 
and luc gene was PCR amplified from pLVX-TetOne™-Puro-Luc and cleaved using the same 
restriction enzymes. Ligation reactions were performed with 1:3, 1:5 and 0.5:3 (vector: 
fragment) molar ratios, being the first more efficient. Moreover, two replication rounds were 
performed, and 7 selected colonies were all positive for the presence of luc gene (Figure 28). 
Correct integration of luc gene was confirmed by sequencing clone 3 with M13F-pUC (-40) 
(Appendix IX).  
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Figure 28. Schematics representing the development and validation of plasmid with Babesia ovata 
elongation factor-1alpha Intergenic region-B driving expression of firefly luciferase (luc) gene (pBovata-luc). 
(A) From left to right: Electrophoresis to define ligation ratios between the plasmid vector resultant from 
pBef1αIG2 restriction digestion with EcoRV and BamHI restriction enzymes and the purified PCR product 
resultant of luc gene amplification from pLVX-TetOne™-Puro-Luc, digested with the same restriction enzymes 
in a 0.8 % (vol/vol) agarose gel. E. coli JM109 colonies resultant from transformation with 1:3, 1:5 and 0.5:3 
(vector: fragment) ligation molar ratios are also observed. (B) Electrophoresis of the PCR products resultant from 
a colony screening PCR targeting luc gene performed to 7 colonies of a second replication round in a 0.8 % 
(vol/vol) agarose gel. N: Negative control. Products approximate size was determined by comparison with 
GeneRuler 1 kb DNA Ladder.   
4.2.3. Development of a promoterless plasmid 
A promoterless plasmid, pBS-luc, was also developed to be used as negative control in 
the luciferase assays. Briefly, pBovata-luc was digested with HindIII restriction enzyme 
excising the 845 bp ef1α-B promoter sequence. After vector re-ligation, validation of promoter 
excision was performed by digestion with HindIII which resulted, as expected in the linearized 
pBS-luc (Figure 29).  
 
Figure 29. Development and validation of the promoterless plasmid (pBS-luc). Electrophoresis of the products 
resultant from restriction digestion of (A) pBovata-luc with HindIII restriction enzyme and (B) promoterless 
plasmid (pBS-luc) with HindIII restriction enzyme in a 0.8% (vol/vol) agarose gel . Products approximate size 
was determined by comparison with GeneRuler 1 kb DNA Ladder. 
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4.3. Preliminary transfection of Babesia ovis by nucleofection 
4.3.1. Transfection of Babesia ovis by nucleofection: a comparison between two nucleofection 
buffers 
Experimental conditions were determined for short term transfection of B. ovis. Until 
now, no pulse condition or relevant nucleofection solution has been recommended by Amaxa 
for nucleofection of Babesia spp. Therefore, the present work initiated with the selection of 
Amaxa nucleofector program V-024 with transfection of 20 µg of plasmid. The initial 
transfection experiments allowed to compare transfection outcomes between two different 
Amaxa nucleofector buffers named “T-cell” and “Parasite”. Evaluation of luminescence 
activity expressed in RLU was performed for a 72h period and transfection efficiency expressed 
in a luc/ “genome” copies ratio was performed 24h post-transfection. Moreover, the effect of 
each nucleofection solution on parasite viability was evaluated 24h after transfection. 
Transfection was performed with both plasmids since no information regarding the 
ability of heterologous promoters to promote expression in B. ovis was available. Initial results 
demonstrated that B. ovis transcriptional machinery had been able to recognize both promoters 
and drive expression of the reporter luciferase. 
Assuming that an increase of transfection experiments would reflect the results herein 
shown, one can suggest that luminescence is equivalent for the same transfected plasmid using 
different transfection buffers, throughout the 72 hours. Negative controls present background 
luminescence (identical to the empty wells). These results are in accordance with a previous 
study in which B. bovis was transfected using two different buffers, the “Plasmodium 88A6”, 
herein named “Parasite” and the “T-cell”. The absolute luminescence values obtained then were 
in the range of the ones obtained for transfection with pBovata-luc and, in agreement with the 
present data, no statistic significant differences were found between the two buffers 92,174.  
Concerning the transfection efficiency, evaluated 24h after transfection, it was possible 
to observe that, for all the plasmid constructs, there is a higher ratio of luc/ “genome copies” 
after transfection with the T-cell buffer, even though this does not correlate with the previous 
luminescence values (Figure 30B). Transfection efficiency was calculated as the ratio between 
luc and BoSPD genes after extracting gDNA from the parasite culture. Since the cytoplasm 
contains nucleases that rapidly degrade free DNA, this assessment is precise in quantification 
of the amount of plasmid DNA that reached the nucleus, supporting the use of this evaluation 
in the present and previous transfection studies 90,95,128,175,176.  
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 Herein, we can observe that transfection with pBovata and pBbovis translates in equal 
luminescence values for both transfections with T-cell and Parasite buffer, but transfection 
efficiency increases between 1.5 to 2 times using the T-cell buffer.  The quantification of a B. 
ovis gene, BoSPD, does not allow to discriminate between death and live parasites 177 which 
will not affect our experiments if using the same transfection conditions between trials. This 
fact will not affect following experiments since the parasite survival post-nucleofection should 
be identical throughout the study. Assuming that this preliminary evaluation is correct, the 
differences between transfection buffers can be explained by the effect of buffers in parasite 
viability (Figure 30C). Thus, while more plasmid DNA entries the nucleus when using the T-
cell buffer, this solution also renders less viable parasites to express the reporter luciferase. The 
equivalent luminescence values indicate that the increase on plasmid DNA entry is inversely 
proportional to parasite survival. The nucleofection process has a clear detrimental effect on 
parasite survival (initial PPE was of approximately 6% for all the transfections carried out), 
however no statistically significant difference was found in the PPE obtained 24h post-
transfection with different buffers (Figure 30C).  
Overall, transfection efficiency of pBbovis-luc is reduced in comparison to the other 
plasmid constructs, suggesting that the lower luciferase expression detected can also be related 
to a lower transfection efficiency and not only with a reduced promoter activity. More 
transfection experiments were performed to evaluate these promoters and are detailed in the 
following section. Considering that no differences were found between the studied buffers in 
luminescence activity and previous nucleofection studies in B. bovis and B. ovata, the human 
T-cell solution transfection solution was selected to further experiments 7,94,108.  
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Figure 30. Transfection of Babesia ovis by nucleofection. (A) Comparison of luciferase expression in B. ovis 
transfected with plasmids pBbovis-luc, pBovata-luc and pBS-luc (negative control) using two different Amaxa 
nucleofector buffers: T-cell and Parasite. The luciferase assays were performed 24h, 48h and 72h post-transfection. 
RLU: Relative Luminescence Units. Data is expressed as the mean of the obtained RLUs for each transfection 
±SD.(n=1) (B) Comparison of transfection efficiency in in B. ovis transfected with plasmids pBbovis-luc, pBovata-
luc and pBS-luc using two different Amaxa nucleofector buffers: T-cell and Parasite 24h post-transfection. A 
qPCR was carried out to assess the number of plasmid DNA copies per “genome” targeting luc and BoSPD genes. 
The ratio of plasmid / “genome copies” was calculated assuming that BoSPD has one copy per genome and used 
has a measure of transfection efficiency. Data is expressed as the mean of luc/”genome” copies ratio obtained from 
three technical replicates for each transfection ±SD. (n=1) (C) Percentage of parasitized erythrocytes (PPE) in B. 
ovis cultures obtained 24h, 48h and 72h after nucleofection with the T-cell buffer and the Parasite buffer. Data is 
expressed as the mean PPE after three independent transfections ±SD. Data obtained 24h post-transfection was 
compared using a paired two sample t test and no statistically significant difference was found among means 
(p<0.05). 
 
4.3.2. Optimal plasmid DNA amount 
To determine the optimal quantity of plasmid for transfection B. ovis , 20 µg or 50 µg 
of pBbovis-luc, pBovata-luc and pBS-luc (using the previously selected T-cell buffer) were 
used. Transfection of more quantity of pBovata-luc correlated with an increase in the RLU 
absolute value (Figure 31A) and, interestingly, when expressing those same RLUs relatively 
to the amount of DNA there is also an increase of the luminescence activity per microgram of 
plasmid (Figure 31B). Regarding pBbovis-luc it was also observed a slight increase on absolute 
luminescence activity when transfecting more quantity of plasmid DNA. However, when the 
data is plotted to express RLU relatively to the DNA amount a slight decrease occurs (Figure 
31A and B). A previous study used varying amounts of plasmid DNA, between 2 µg and 200 
µg, demonstrating that increasing the amount of plasmid DNA correlates with a decrease in the 
RLU/µg values 92. In that study, data suggests that the increase of plasmid DNA from 20 µg the 
50 µg correlates with a slight decrease in the RLU/µg value which our transfection experiment 
with pBbovis-luc corroborates. However, a more recent study with transfection of B. ovata 
reports that increasing the amount of plasmid DNA from 50 µg to 100µ correlates with an 
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increase in transfection efficiency 94. In the conditions undertaken in the present study, higher 
plasmid DNA did not show to affect parasite viability since no statistically significant 
differences were found when comparing different plasmid amounts (Figure 31C). In a previous 
study it was found that increasing the plasmid amount would correlate with a decrease on 
parasite viability however in it was only evaluated transfection with 2 µg and 200 µg, so this 
data cannot be compared with the presently obtained 92. 
At the light of the results obtained, the following transfection experiments were 
conducted using 20 µg of plasmid DNA.  
 
 
Figure 31. Transfection of Babesia ovis using varying amounts of plasmid DNA. (A) Comparison of luciferase 
activity 24 h, 48 h and 78 h post-nucleofection with varying amounts (20 µg and 50 µg) of pBbovis-luc, pBovata-
luc and pBS-luc (negative control)(n=1). (B) Comparison of  the ratio of luciferase activity relatively to the amount 
of DNA transfected. RLU: Relative Luminescence Units. Data is expressed as the mean of the obtained RLUs for 
each transfection ±SD (n=1). (C) Percentage of parasitized erythrocytes (PPE) in B. ovis cultures obtained 24h, 
48h and 72h after nucleofection with 20 µg and 50 µg of plasmid DNA. Data is expressed as the mean PPE after 
three independent transfections ±SD. Data obtained 24h post-transfection was compared using a paired two sample 
t test and no statistically significant difference was found among means (p<0.05). 
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Noteworthy, in these initial transfection experiments a positive control was also 
included, the pmaxGFPTM vector supplied by Amaxa biosystems. This expression vector has a 
CMV promoter, and until now, thought that this promoter was not recognized by apicomplexan 
parasites transcriptional machinery 125,126.  Herein, activity was observed, urging additional 
studies to clarify if B. ovis transcriptional machinery is indeed able to recognize CMV promoter 
sequence.  
 
Figure 32. Fluorescence microscopy image of Babesia ovis expressing green fluorescent protein (GFP) after 
transfection with pmaxGFPTM vector. Intraerythrocytic parasites were observed under a 400x original 
magnification of a Nikon eclipse 80i fluorescence microscope with the GFP filter. Scale-bar:5 μm 
4.4. Babesia bovis and Babesia ovata elongation factor-1alpha intergenic region-B have 
heterologous promoter activity in Babesia ovis  
The promoter activity of B. bovis and B. ovata ef-1 IG-B regions were tested using 
luciferase assays.  Both promoter regions used in the present study were previously validated 
concerning their ability to drive expression of a reporter gene in their respective species 94,108. 
After transfection with the transient plasmid constructs developed (Figure 33A), luciferase 
expression was evaluated for a time lapse of 24h-72h post B. ovis nucleofection. It was observed 
maximum luciferase expression at 24h post-transfection with either pBbovis-luc and pBovata 
and, 72h post-transfection, the luminescence expression is negligible (Figure 33B). In a recent 
study, B. bovis was transfected with a plasmid containing B. bigemina ef-1α IG-B driving 
expression of a reporter luciferase and a similar pattern of luciferase expression was observed 
throughout the 72h period, with the peak of luciferase expression occurring 24h post-
transfection 95. Similarly, transient transfection of B. gibsoni with the homologous 5’ ef-1α 
driving expression of the same reporter gene resulted in a decrease of luminescence along the 
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72h period 97. In contrast, another study in B. ovata with a homologous promoter driving 
expression of a reporter luciferase shows a peak of luciferase activity 48h post-transfection an 
expression that is maintained until 96h 94. These differences are probably related with the 
different growth rate of these different species since upon cell division the transiently 
transfected genetic material is lost (Figure 34) 85,97. 
Herein, we demonstrate that both B. ovata and B. bovis ef-1α IG-B regions are 
recognized by B. ovis transcriptional machinery, being able to drive expression of a reporter 
luciferase. Furthermore, B. ovata ef-1α-B promoter region can induce expression of higher 
levels of luciferase indicating that B. ovis transcription factors have a higher binding affinity 
towards motifs existent in B. ovata ef-1α IG-B region 120. These transcription factors can be 
either sequence-specific DNA-binding proteins involved in specific regulation of a certain gene 
or more general, related with RNA polymerase II components required for transcription 
initiation. However, absence of knowledge regarding B. ovis cis-regulatory motifs does not 
allow to infer which binding factors might be weighting in the presently obtained results 113,119. 
Recently, it was attempted to transfect B. ovata with a plasmid having B. bovis ef-1α IG-B 
region, but this region was not able to induce expression of the reporter luciferase, a fact 
attributed to a lack of recognition by either B. ovata transcriptional or translational machinery 
94. Therefore, one can suggest that the sequence of B. bovis ef-1α IG-B does not have certain 
motifs necessary for transcription factor recognition by B. ovata, being probably quite different 
from the B. ovata homologous ef-1α IG-B sequence. Thus, supporting the differences observed 
in the luciferase expression of these promoter regions in B. ovis.  
Another fact that can explain the differences observed in luciferase expression is 
transfection efficiency (Figure 33C). However, no significant differences in transfection 
efficiencies were found between pBbovis and pBovata this last hypothesis can be precluded 
and vehemently suggest that B. ovis transcriptional factors have a stronger affinity for B. ovata 
than for the B. bovis ef-1a-B promoter sequence.  
The present results also indicate that both B. bovis and B. ovata 3’ rap-1 terminator 
regions have a cross-species function in B. ovis. The cross-species function of this region had 
only been described once before with B. bovis 3’ rap-1 terminator region being functional in B. 
gibsoni 100. A study that analysed rap-1 IG regions from B. bovis, B. bigemina, B. canis and B. 
ovis concluded that the sequence conservation between species was relatively low with the 
highest sequence similarity (42% identity) being found between B. ovis and B. bovis sequences 
157. It appears that both B. bovis and B. ovata rap-1 IG regions have the necessary termination 
signals to be functional in B. ovis. 
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Figure 33. Schematic diagram of the plasmids used for transient transfection and evaluation of Babesia 
bovis and Babesia ovata elongation factor-1alpha intergenic region-B heterologous promoter activity in 
Babesia ovis. (A) Transient transfection constructs with B. bovis and B. ovata ef-1α-B promoter sequence driving 
expression of luciferase as a reporter were developed as well as a promoter-less plasmid to use as negative control. 
(B) Evaluation of the promoter activity of B. bovis and B. ovata ef-1α IG-B driving expression of a reporter 
luciferase over a time lapse of 24-72h post-transfection in B. ovis. Negative control was performed through 
transfection of a promoter-less plasmid. Data are expressed as the mean of the obtained RLUs of three independent 
transfections with each plasmid (B. bovis ef-1α IG-B, B. ovata ef-1α IG-B and promoter-less plasmid) + SD. RLU: 
Relative luciferase units. Data were compared using One-way ANOVA analysis, with no significant differences 
(P < 0.05) detected, ( F(2,6)=1.989, P=0.2174 at 24h, F(2,6) =1.306, P=0.3383 at 48h and F(2,6) =1.73, P=0.2552 
at 72h).(C) Evaluation of transfection efficiency of the plasmid constructs by the luc/”genome copies” ratio. A 
qPCR was carried out to assess the number of plasmid DNA copies per “genome” 24h post-transfection targeting 
luc and BoSPD genes. The ratio of plasmid /”genome copies” was calculated assuming that BoSPD has one copy 
per genome.  No statistically significant differences among the plasmids transfected were found (One-way 
ANOVA Analysis (p < 0.05), F(2,6) =1.053, P=0.4055) 
 
Figure 34. Time course of luciferase activity and parasitemia measured at 24h, 48h and 72h post-
transfection with pBovata-luc. RLU: Relative luciferase units. PPE: Percentage of parasitized erythrocytes. Data 
is expressed as the mean of three independent transfections ±SD. 
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4.5. Growth inhibition of B. ovis by blasticidin-S and the effect of WR99210 in in vitro 
cultures  
To determine if WR99210 could inhibit B. ovis in vitro growth as well as a suitable 
concentration for selection of transgenic parasites, B. ovis Israeli strain was subjected to 
different drug concentrations ranging from 0 to 50 nM. The initial PPE for all the culture wells 
was 1% and it was determined daily for a period of 72h. The results showed that after 3 days of 
drug selection only 17,7% of growth inhibition was achieved at the higher concentration tested 
and it was not possible to determine the drug IC50. No significant differences between the PPE 
attained in the culture wells exposed to different drug concentrations and the control wells (only 
with DMSO, the drug vehicle) (Figure 35) was determined. Thus, WR9910, showed not to be 
an efficient B. ovis growth inhibitor. Interestingly, these results are contrary to what is described 
for other WR99210 sensitivity assays in Babesia spp. For B. bovis the IC50 determined was 1.0 
nM and, at a concentration of 5 nM, parasite growth was completely inhibited, similar to the 
growth inhibitory concentrations found in Plasmodium parasites 7,108,178 For B. ovata, WR99210 
completely inhibits in vitro growth at a nanomolar concentration (5 nM) with an IC50 of 0.56 ± 
0.01 nM and for B. gibsoni the calculated IC50 was 1.1 nM, similar to the described for B. bovis, 
with the drug at 10 nM completely inhibiting the parasite growth 94,98.  
 
 
 
 
 
 
 
 
 
Figure 35. In vitro growth curve (A) and growth inhibition of Babesia ovis Israeli strain with WR99210 (B). 
Parasite cultures were subjected to different concentrations of WR99210 (0-50 nM) and the percentage of 
parasitized erythrocytes (PPE) was determined every 24h over a period of 72h. All data are expressed as the 
arithmetic means ± SD of the triplicate cultures  
Reports from different research groups assign the lack of growth inhibition to the drug 
manufacturer. Thus, this is the most plausible explanation for WR99210 failure to inhibit B. 
ovis in vitro growth more than the achieved 17,7%. The presence of polymorphic copies of the 
dhfr gene in B. ovis genome that would reduce the parasite sensitivity to this antifolate drug can 
A B 
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also be considered. However, the non-emergence of naturally resistant parasites in previous 
selected transfected Babesia spp.  does not support this hypothesis94,98.  To consider 
WR99210/dhfr as selection system for B. ovis, higher drug concentrations would need to be 
evaluated. 
Given the previous results, blasticidin-S was evaluated as an alternative antibiotic. 
Similarly, B. ovis Israeli strain was cultured in the presence of different blasticidin S 
concentrations, ranging from 0 μg/mL to 28.8 μg/mL for a period of 72h with PPE being 
monitored in a daily basis. The results show that increasing blasticidin concentration above 4.8 
μg/mL correlates with a decreasing PPE at 24h and after 48h this value is lower with drug 
concentration above 2.4 μg/mL correlating with a decrease in PPE (Figure 36A). At 72h, 
blasticidin-S concentrations above 4.8 μg/mL result in negligible parasite growth (Figure 36B 
and Appendix X.1). To ensure that concentrations above 19.2 μg/μL inhibited completely 
parasite growth the cultures subjected to that concentration range were maintained for more 96 
hours without the drug pressure to confirm that the parasites observed in the end of the 
sensitivity assay were not able to re-infect other erythrocytes. Indeed, after that period no 
parasites were observed. 
 The calculated IC50 found was approximately 2.3 μg/mL and concentrations in 4.8 – 
28.8 μg/mL range are suggested to inhibit completely parasite growth. Interestingly, the 
obtained results are quite different from the ones obtained in the first sensitivity assay 
performed in B. bovis, for which the blasticidin-S calculated IC50 was 0.4 μg/mL and the 
concentration range of 0.64–1.25 μg/mL resulted in negligible parasite growth 93. In a recent 
study, the calculated IC50 for B. bovis was 0.8 µg/mL and concentrations between 3 µg/mL and 
9 µg/mL completely inhibited parasite growth. In the same study, the IC50 for B. bigemina was 
3 µg/mL and drug concentrations between 8 µg/mL and 14 µg/mL would correlate with 
complete in vitro growth inhibition, results more similar to the found for B. ovis in the present 
study 96.  
Overall, the present results demonstrate the suitability of using blasticidin-S/bsd 
selection system in the development of a stable transfection system for B. ovis. Moreover, the 
resistant determinant, the bsd gene is encoded by a small ORF (399 bp) which further enhances 
the probability of an efficient transfection and allows the cloning of larger DNA fragments 
without compromising transfection efficiency 142. 
 
.  
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Figure 36. In vitro growth curve (A) and growth inhibition of Babesia ovis Israeli strain with blasticidin-S 
(B). Parasite cultures were subjected to different concentrations of blasticidin (0-28.8 μg/mL) and the percentage 
of parasitized erythrocytes (PPE) was determined every 24h over a period of 72h. All data are expressed as the 
arithmetic means ± SD of the triplicate cultures 
4.6. Construction and preliminary validation of a recombinant plasmid expressing an 
RFP-BSD fusion protein 
The mechanisms for integration of exogenous DNA and the occurrence of legitimate 
recombination events involving sequences in the transfection plasmid (promoter, terminator 
and flanking regions) were studied in B. bovis. The pattern of integration consisted mainly in 
the disruption of the ef-1α-B gene, and as so the design of the transfection plasmid included 5’ 
and 3’ ef-1α-B  as flanking regions. However, another observable pattern of integration included 
part of the ef-1α-B promoter sequence in the recombination event. This led to endorse the use 
of heterologous promoter and terminator regions in future transfection plasmids 8. Thus, results 
obtained so far, supported the use of B. ovata ef-1a-B promoter region to drive expression of 
an RFP-BSD fusion protein in a future stable transfection system aiming genome integration 
by disruption of B. ovis ef-1a-B gene.  
The pBrfp-bsd was used as backbone for the development of pBovata-rfp-bsd (Table 
2). Briefly, the pre-existing B. bovis ef-1α IG-B region was excised from the plasmid and 
replaced by B. ovata ef-1α IG-B region. To achieve this, the plasmid was cleaved with SalI and 
HindIII and isolated from the gel. In parallel, B. ovata ef-1α IG-B region was amplified by PCR 
from pBef1αIG2, purified and cleaved with the same restriction enzymes (Figure 37A). 
Ligation was performed and E. coli JM109 colonies appeared after transformation with the 
ligation reaction. Validation of the presence of fragment was performed by colony screening 
PCR targeting the B. ovata ef-1α IG-B and, throughout two replication rounds performed to 7 
B A 
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selected colonies, all the clones were positive for the presence of B. ovata ef-1α IG-B region 
(Figure 37B).  
 
Figure 37. Schematics of the development of a plasmid with Babesia ovata elongation factor-1alpha 
Intergenic region-B region driving expression of red fluorescent-blasticidin-S deaminase fusion protein. (A) 
From left to right: Electrophoresis of pBrfp-bsd restriction of pBrfp-bsd with SalI and HindIII in a 0.8 % (vol/vol) 
agarose gel and of the purified PCR product resultant of B. ovata ef-1α IG-B amplification digested with the same 
restriction enzymes in a 1.2 % (vol/vol) agarose gel. Ampicillin resistant clones obtained after transformation of 
E. coli JM109 . (B) Colony screening PCR targeting B. ovata ef-1α IG-B from 7 colonies of a second replication 
round of the primary colonies after transformation. N: PCR negative control. Products approximate size was 
determined by comparison with (A) GeneRuler 1 kb DNA Ladder and NZYDNA Ladder VI or (B) GeneRuler 1 
kb DNA Ladder. 
 The RFP-BSD fusion protein functionality has been previously validated in 
transfections experiment in B. bovis 108,179. Regarding the ability of B. ovata ef-1α IG-B region 
to drive expression of this fusion protein in B. ovis it was confirmed by the observed 
chemiluminescence as shown in the previous section (Figure 33). Nonetheless, transient 
transfection of B. ovis with pBovata-rfp-bsd was carried out to confirm expression of the fusion 
protein and, fluorescence microscopy revealed the presence of B. ovis transiently expressing 
the RFP-BSD fusion protein (Figure 38).  
 
Figure 38. Fluorescent microscopy image of Babesia ovis transiently expressing the red fluorescent protein 
(RFP).  Intraerythrocytic parasites were observed under a 100x original magnification of a Nikon eclipse 80i 
fluorescence microscope with the RFP filter.  
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5. Conclusions and Future Perspectives 
B. ovis was successfully transfected for the first time with the establishment of a baseline 
protocol for future transfections of this parasite. The constructs with ef-1α IG-B from B. bovis 
and B. ovata driving expression of a reporter luciferase were developed. Both promoter regions 
were recognized by B. ovis transcriptional factors although the ef-1α-B promoter region from 
B. ovata showed to have a stronger affinity . The present work sustains previous reports of 
interspecies promoter activity between Babesia spp. Regrettably, given the absence of B. ovis 
ef-1α IG-B region, the interchangeable cross-species activity of this promoter region could not 
be explored. 
B. ovis ef-1α gene was revealed to have high nucleotide sequence homology so the 
design of a transfection plasmid including 5’ and 3’ ef-1α-B as flanking regions is potentially a 
platform to stably transfect other Babesia spp. The establishment of this stable transfection 
platform common to several species appears to be feasible for at least B. ovis and B. ovata.  
Currently, the development of a stable transfection system in ongoing. This will allow 
to have a B. ovis lineage stably expressing RFP, an essential tool to understand B. ovis and 
related Babesia spp. life cycle events in the tick vector tissues. Nevertheless, with the 
establishment of such system, new avenues related with functional gene characterization 
through gene knockout experiments and novel vaccine development are also open. For the latter 
and considering that Theileria ovis and B. ovis co-infection is common, an attenuated B. ovis 
stably expressing a T. ovis antigen could be a vaccine delivery platform enabling host immunity 
against both pathogens.  
Advancing in the development of these transfection methods could allow using them to 
study key motifs essential for promoter activity. Such studies would result in the development 
of more efficient stable constructs, refining all the applications of this genetic manipulation 
method.  
The development of both transient and stable transfection systems can be simplified 
with the release of the full genome sequence of B. ovis Israeli strain. The accessibility of such 
genomic sequences can clarify functions of proteins implicated in virulence and identify more 
candidates for vaccine development which can be accelerated with the application of genetic 
tools.  
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7. Appendix  
Appendix I 
Appendix I.1: Babesia ovis actin partial coding sequence obtained in the present study.  
GGAAAGAACCTATGTTGGAGATGAGCACAGGCTAAGCGTGGTATCTTGACCCTTAAATACCCAATCGA
GCATGGTATTGTCACCAACTGGGAGGATATGGAGAAAATCTGGCATCACACCTTCTACAATGAGCTTC
GTATTGCCCCTGAGGAACACCCAGTGCTGTTGACCGAAGCTCCCATGAACCCCAAGGCCAACCGTGAA
AAGATGACTACCATTATGTTCGAAACCCACAACGTGCCAGCTATGTATGTTGCTATCCAAGCCGTGCT
TTCGCTGTACTCGTCTGGTCGTACCACTGGTATTGTGCTCGACTCTGGTGATGGTGTCACCCACACCG
TCCCTATCTACGAGGGTTACGCCCTTCCCCATGCCATTATGCGTATTGACCTTGCCGGTCGTGACCTT
ACTGAGTTCATGCAAAAGATCTTGGCTGAACGTGGTTTCACCTTCACCACCACTGCCGAAAAGGAAAT
TGTGCGTGACATCAAGGAGAAATTGTGTTACATTGCACTCGACTTCGAAGAGGAAATGAACTCTTCTG
CCTCATCAAGTGAAATCGAAAAATCTTACGAACTGCCTGATGGAAACATCATCACTGTCGGAAACGAG
CGTTTCAGGTGCCCTGAGGTGCTCTTCCAACCAAGCTTCATTGGCCAAGAGTCTGCCGGTATCCACAC
CACTACCTTCAACTCAATTGCCCGTTGTGATGTCGACATCCGCAAGGACCTTTACGCAAATGTCGTCC
TTTCTGGTGGTACAACCATGTACGAGGGTATAGGCCAGCGTATGACCAAGGAGCTTAACGCTCTTGTA
CCCAGCACCATGAAGATCAAGGTCGTTGCCCCTCCTGAGCGCAAGTACTCTGTATGGATTGGAGGATC
TATTCTTTCTTCGTTGTCCACATTCCAGCAGATGTGGATCACTAAGGAGGAGTTCGACGAGTCTGACC 
Appendix I.2: Alignment between the sequence obtained in the present study and Babesia ovis 
actin coding sequence retrieved from B. ovis Israeli strain draft genome (Bo_actin_CDS (g767) 
1496356…1497486). 
 
Bo.actin.partial      ------------------------------------------------------------ 0 
Bo.actin.CDS          ATGTCGGACGAAGAGGCTACCGCTTTGGTCATTGACAATGGATCCGGTAATGTCAAGGCC 60 
                                                                                   
 
Bo.actin.partial      ------------------------------------------------------------ 0 
Bo.actin.CDS          GGTGTTGCTGGAGACGATGCTCCCCGCTGCGTTTTCCCCAGCATTGTAGGTCGCCCAAAG 120 
                                                                                   
 
Bo.actin.partial      ------------------------------GGAAAGAACCTATGTTGGAGATGAGCACAG 30 
Bo.actin.CDS          AACCCAGCCCTTATGGTTGGTATGGACGAAAAGGACACCTATGTTGGAGATGAAGCACAG 180 
                                                        * * *     * *      ******* 
 
Bo.actin.partial      GCTAAGCGTGGTATCTTGACCCTTAAATACCCAATCGAGCATGGTATTGTCACCAACTGG 90 
Bo.actin.CDS          GCTAAGCGTGGTATCTTGACCCTTAAATACCCAATCGAGCATGGTATTGTCACCAACTGG 240 
                      ************************************************************ 
 
Bo.actin.partial      GAGGATATGGAGAAAATCTGGCATCACACCTTCTACAATGAGCTTCGTATTGCCCCTGAG 150 
Bo.actin.CDS          GAGGATATGGAGAAAATCTGGCATCACACCTTCTACAATGAGCTTCGTATTGCCCCTGAG 300 
                      ************************************************************ 
 
Bo.actin.partial      GAACACCCAGTGCTGTTGACCGAAGCTCCCATGAACCCCAAGGCCAACCGTGAAAAGATG 210 
Bo.actin.CDS          GAACACCCAGTGCTGTTGACCGAAGCTCCCATGAACCCCAAGGCCAACCGTGAAAAGATG 360 
                      ************************************************************ 
 
Bo.actin.partial      ACTACCATTATGTTCGAAACCCACAACGTGCCAGCTATGTATGTTGCTATCCAAGCCGTG 270 
Bo.actin.CDS          ACTACCATTATGTTCGAAACCCACAACGTGCCAGCTATGTATGTTGCTATCCAAGCCGTG 420 
                      ************************************************************ 
 
Bo.actin.partial      CTTTCGCTGTACTCGTCTGGTCGTACCACTGGTATTGTGCTCGACTCTGGTGATGGTGTC 330 
Bo.actin.CDS          CTTTCGCTGTACTCGTCTGGTCGTACCACTGGTATTGTGCTCGACTCTGGTGATGGTGTC 480 
                      ************************************************************ 
 
Bo.actin.partial      ACCCACACCGTCCCTATCTACGAGGGTTACGCCCTTCCCCATGCCATTATGCGTATTGAC 390 
Bo.actin.CDS          ACCCACACCGTCCCTATCTACGAGGGTTACGCCCTTCCCCATGCCATTATGCGTATTGAC 540 
                      ************************************************************ 
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Bo.actin.partial      CTTGCCGGTCGTGACCTTACTGAGTTCATGCAAAAGATCTTGGCTGAACGTGGTTTCACC 450 
Bo.actin.CDS          CTTGCCGGTCGTGACCTTACTGAGTTCATGCAAAAGATCTTGGCTGAACGTGGTTTCACC 600 
                      ************************************************************ 
 
Bo.actin.partial      TTCACCACCACTGCCGAAAAGGAAATTGTGCGTGACATCAAGGAGAAATTGTGTTACATT 510 
Bo.actin.CDS          TTCACCACCACTGCCGAAAAGGAAATTGTGCGTGACATCAAGGAGAAATTGTGTTACATT 660 
                      ************************************************************ 
 
Bo.actin.partial      GCACTCGACTTCGAAGAGGAAATGAACTCTTCTGCCTCATCAAGTGAAATCGAAAAATCT 570 
Bo.actin.CDS          GCACTCGACTTCGAAGAGGAAATGAACTCTTCTGCCTCATCAAGTGAAATCGAAAAATCT 720 
                      ************************************************************ 
 
Bo.actin.partial      TACGAACTGCCTGATGGAAACATCATCACTGTCGGAAACGAGCGTTTCAGGTGCCCTGAG 630 
Bo.actin.CDS          TACGAACTGCCTGATGGAAACATCATCACTGTCGGAAACGAGCGTTTCAGGTGCCCTGAG 780 
                      ************************************************************ 
 
Bo.actin.partial      GTGCTCTTCCAACCAAGCTTCATTGGCCAAGAGTCTGCCGGTATCCACACCACTACCTTC 690 
Bo.actin.CDS          GTGCTCTTCCAACCAAGCTTCATTGGCCAAGAGTCTGCCGGTATCCACACCACTACCTTC 840 
                      ************************************************************ 
 
Bo.actin.partial      AACTCAATTGCCCGTTGTGATGTCGACATCCGCAAGGACCTTTACGCAAATGTCGTCCTT 750 
Bo.actin.CDS          AACTCAATTGCCCGTTGTGATGTCGACATCCGCAAGGACCTTTACGCAAATGTCGTCCTT 900 
                      ************************************************************ 
 
Bo.actin.partial      TCTGGTGGTACAACCATGTACGAGGGTATAGGCCAGCGTATGACCAAGGAGCTTAACGCT 810 
Bo.actin.CDS          TCTGGTGGTACAACCATGTACGAGGGTATAGGCCAGCGTATGACCAAGGAGCTTAACGCT 960 
                      ************************************************************ 
 
Bo.actin.partial      CTTGTACCCAGCACCATGAAGATCAAGGTCGTTGCCCCTCCTGAGCGCAAGTACTCTGTA 870 
Bo.actin.CDS          CTTGTACCCAGCACCATGAAGATCAAGGTCGTTGCCCCTCCTGAGCGCAAGTACTCTGTA 1020 
                      ************************************************************ 
 
Bo.actin.partial      TGGATTGGAGGATCTATTCTTTCTTCGTTGTCCACATTCCAGCAGATGTGGATCACTAAG 930 
Bo.actin.CDS          TGGATTGGAGGATCTATTCTTTCTTCGTTGTCCACATTCCAGCAGATGTGGATCACTAAG 1080 
                      ************************************************************ 
 
Bo.actin.partial      GAGGAGTTCGACGAGTCTGACC----------------------------- 952 
Bo.actin.CDS          GAGGAGTTCGACGAGTCAGGACCAAACATTGTCCACAGAAAATGCTTCTAA 1131 
                      ***************** *  *                              
 
Appendix I.3: Babesia ovis actin 5’ flanking region retrieved from B. ovis Israeli strain draft 
genome. 
CACAAGTAATGTTAGTTATAATGTATGAACGAATATAATTTTTGTGCCATGAGATAATGTATAATATT
TTTTACAGCAGAAAACGTTGCGTGATGAAGGGGAAGTACACATCTGGCATATGATTACCAGTACTACT
GAAGCATACACGAGACAAATGGAGGCTAGTTACGTAAACGCGGGGACCGTTGTGAATTTCGAAAGCAT
CAATCGCACTATAGAGCAAAGGTTAAATAAAGGTAATCTAGCCAATATGAGCGATGTTTGTGAATATG
ATCGTGACTCATATATTGGTATGGTTTACAAGGATGTATCTACCATGATCTGCGAGTAAGGTGACTTC
AAGATGCATTATGTAACTGGTAATAGTCACTTGTAACGGGCACCACCTAAGCACAGGGCAGTACAAAC
AGACGAGGTTAAGCTTGAATCGAAAAATATTGATATAAGCATCGGCAGACCAATGTGTTGGAGTTAAC
AGCTGTGTTAGCGACGCGTACTCCATAGCAAGGCACCGCTGCTGCCGCAGGAGATCGAAGGTCGCCCC
ACGGGCATTGATGTTTCCTCGATCCCACAAGCACAACTGTGTCGTAGTTCATACACTCTTTTTGGAAC
ATAGCTAAACGATTCCTATTGAACTTTTACTTTTGCGTAGTCCCTTAGAGGTAAGTGGTACGACAAAT
CATGGGCCTGCACAGTAGAAGCACATGTGTATATCCAAAGTGCTATGGCCTGCATCATCTTGCGCATT
TCAAAATTGTGGAGATGGTACAAAATTATTGTCAACATGCCCATTGAAATGCACTGGATGCATTAGTT
GATGTGCAAGCTCCGTGATTTTAATCTTTAGTTACATGAAACTACGTGCGACGCGATCCCCAAGGATG
CGCGACACCGGCATGATCGAATCAACGCGAGCACTGAATTCTCTGTCACGTGTTCATGTATATTCCAA
ATTTTATTAGCATCTCTCATACTTGCTCAGAAATAGTAATTCGAAAAA 
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Appendix I.4: Babesiidae annotated sequence producing significant alignments with the B. ovis 
actin 5’ flanking region sequence. 
 
Description 
Maximum 
Score 
Total 
Score 
Percent 
Query 
Coverage 
Expect 
Value 
Maximum 
Percent 
Identity 
GenBank 
Accession 
Number 
Babesia bovis strain 
Texas actin gene, 
promoter region 
116 116 40% 1-23 68% MF598086.1 
 
Appendix II 
Appendix II.1: Babesia ovis sequencing result of the 1500 bp amplicon obtained with the sequence 
similarity approach. 
TCCACTTTACGTCGCTGACTAGTGAACTTTTTACAAATAAATCATTATTGCACTATACCAAGTTTGCG
TTTGCAGTTATCTGACATGACATCTAGCTCCTGCTTCGTGAATTCCAGGAGGTTCTCTGGCACGAAGA
CATCAGTGTTGGGGTTGTGCAGTATATCATTGAAGAACTCGTGACTGAGGGCTTCAAGTGGTTGGACA
CGTTCCTTTGGATCGTATCGTAAAAATTGTGCTACAAAGTCGATAGCGACTGGGGGTGTATTTTTGGG
GAACACTTTGGAGAGATCCGCTGGTCTGATATTTGGGAATGTGACATTTTGATAGTTGGGATGCATGG
CGTACATCTGTTCGATTGTTGGTGTCCCCAATACCTGTATGATCTTGACGAGCTGATCAATTGATGTG
TCTCCGGCGAACATGGGTTTACCCATTAGTAGCTCTCCGATGACACACCCAACGGACCATATATCTAT
GGCAGTGGTATATTCCGTTGCTCCAAGCATGAGCTCAGGAGCCCTGTAAAATCTTGAACAAATGTATG
CAACGCTCATTTCACCGGCAAGCAATTTCTTGGCTGACCCAAAGTCGCAAAGTTTGanaa 
ACAACAAGCATAGCAACATCGGTTACGCCACAAGCAAGACGTACTTGGACGTTAAGGGTATAAATAAA
GGTGTCAAGAATGCTCAAACCACAAGTGTGATAGCTCTGAATGCGCAAAATACAACGATGCCCGGAGG
AAATACGCATAGCACAAAGGCGTCCACCGCGGACACACAGAGCACAAAGGGAACTGCCGCAGATACGC
AGAACTCGGGGATGACTAACTCGGACAATGGCACATATCTAAATGTGGAATTTAATAATGAAAGTCTG
ATGATAGCTTACTCCAAGCCACCGGGGACAACGACGTTGCGACCTCCCGAACGCCAAGACGTAGTTCA
GGCGCAAAGTCGCCATCCACATGCCCTTCAGGGCAATTCACAAGGAGGATCTAATGTCAAAGTAGCTG
AAGGGACACAAGATATGAATACGTCGGTTGGTGGGAACCAGCCTGCACAACTGCGGGGCGCAGACACA
CAAACAAGCACCGATAGCAAATACCAAGTCCAACGAATGATAGGTAATGGGTCATTCGGAGTTGTGCA
TGAAGCAGTTCATGTGGAAACCGGTAGGCGCTTTGCCATAAAGAAGGTTCTACAGGTATTGTTTTTGA
AATGTTTGTATCATAGATATCCAGGATCCACGTTATAAAAATCGGGGAACTCAGCATCATGctggGAA
CTCTCTCACCCAAATATtGnATATATGTTTGaCC
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Appendix III 
Appendix III.1: Babesia ovis elongation factor 1 α partial coding sequence obtained in the present 
study. 
TTCAAGTACGGCCTGGGTTTTGGACAAGCTGAAGAGTGAGCGTGAACGTGGTATCACCATCGATATCA
CCCTGTGGAAGTTCGAAACCTCTAAGTACTACTACACTGTCATTGACGCCCCTGGTCACCGTGACTTC
ATCAAGAACATGATTACGGGTACCTCCCAGGCCGATGTGGCTATGCTTGTGGTGCCAGCTGAGGCTGG
TGGTTTCGAGGCTGCCTTCTCCAAGGAAGGTCAGACCCGTGAGCACGCTCTTTTGGCCTTCACCCTCG
GTGTCAGGCAGATTATTTGCGCCATCAACAAGATGGACAAGTGCGACTACAAGGAGGACCGTTACAGT
GAAATCCAGAAGGAAGTCCAGGGATACCTCAAGAAGGTCGGTTACAACACCGATAAGGTTCCCTTCGT
TGCCATCTCCGGTTTCATGGGTGACAACATGGTTGAGCGCTCCACCAACATGCCATGGTACAAGGGCA
AGACCTTGGTCGAGGCCCTCGACATGATGGAGCCCCCAAAGAGGCCCGTTGACAAGCCACTTCGTCTT
CCCATCCAGGGTGTCTACAAGATCGGTGGTATCGGTACCGTGCCCGTCGGTCGTGTCGAGACTGGTCA
GCTCAAGGCTGGTATGGTCCTCACCTTCGCCCCCAACCCCATCACCACCGAGTGCAAATCTGTTGAAA
TGCACCACGAAGTCGTTGAGGTTGCCTACCCTGGTGACAACGTCGGTTTCAACGTAAAGAACGTGTCT
ACCTCTGACATCCGCAGTGGTCACGTCGCCTCCGACTCCAAGAACGACCCCGCCAAGGCCGCTGTGTC
CTTCAGCGCCCAGGTCATTGTGCTTAACCACCCTGGTAACATCAAGGCTGGTTACACCCCCGTTGTTG
ACTGTCACACTGCCCACGTTTCCTGCAAGTTCGACGAGATCACCTGCCGTATGGAC 
Appendix III.2: Alignment between the sequence obtained in the present study and Babesia ovis 
elongation factor 1α coding sequence retrieved from B. ovis Israeli strain draft genome 
(Bo_EFG_CDS (g3736) 749836…7499712). 
 
Bo.ef.partial      ------------------------------------------------------------ 0 
Bo.ef.CDS          ATGCCGAAGGAGAAGACCCACATTAACTTGGTCGTTATCGGCCACGTCGACAGTGGCAAG 60 
                                                                                
 
Bo.ef.partial      ------------------------------------------------------------ 0 
Bo.ef.CDS          TCGACCACCACTGGTCACTTGATCTACAAGCTTGGTGGTATTGACAAGCGTACCATCGAG 120 
                                                                                
 
Bo.ef.partial      --------------------------------------TTCAAGTACGGCCTGGGTTTTG 22 
Bo.ef.CDS          AAGTTCGAGAAGGAATCCACCGACATGGGTAAGGGTTCGTTCAAGTACGCCTGGGTCTTG 180 
                                                          *  *     ******** *** 
 
Bo.ef.partial      GACAAGCTGAAGAGTGAGCGTGAACGTGGTATCACCATCGATATCACCCTGTGGAAGTTC 82 
Bo.ef.CDS          GACAAGCTGAAGAGTGAGCGTGAACGTGGTATCACCATCGATATCACCCTGTGGAAGTTC 240 
                   ************************************************************ 
 
Bo.ef.partial      GAAACCTCTAAGTACTACTACACTGTCATTGACGCCCCTGGTCACCGTGACTTCATCAAG 142 
Bo.ef.CDS          GAAACCTCTAAGTACTACTACACTGTCATTGACGCCCCTGGTCACCGTGACTTCATCAAG 300 
                   ************************************************************ 
 
Bo.ef.partial      AACATGATTACGGGTACCTCCCAGGCCGATGTGGCTATGCTTGTGGTGCCAGCTGAGGCT 202 
Bo.ef.CDS          AACATGATTACGGGTACCTCCCAGGCCGATGTGGCTATGCTTGTGGTGCCAGCTGAGGCT 360 
                   ************************************************************ 
 
Bo.ef.partial      GGTGGTTTCGAGGCTGCCTTCTCCAAGGAAGGTCAGACCCGTGAGCACGCTCTTTTGGCC 262 
Bo.ef.CDS          GGTGGTTTCGAGGCTGCCTTCTCCAAGGAAGGTCAGACCCGTGAGCACGCTCTTTTGGCC 420 
                   ************************************************************ 
 
Bo.ef.partial      TTCACCCTCGGTGTCAGGCAGATTATTTGCGCCATCAACAAGATGGACAAGTGCGACTAC 322 
Bo.ef.CDS          TTCACCCTCGGTGTCAGGCAGATTATTTGCGCCATCAACAAGATGGACAAGTGCGACTAC 480 
                   ************************************************************ 
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Bo.ef.partial      AAGGAGGACCGTTACAGTGAAATCCAGAAGGAAGTCCAGGGATACCTCAAGAAGGTCGGT 382 
Bo.ef.CDS          AAGGAGGACCGTTACAGTGAAATCCAGAAGGAAGTCCAGGGATACCTCAAGAAGGTCGGT 540 
                   ************************************************************ 
 
Bo.ef.partial      TACAACACCGATAAGGTTCCCTTCGTTGCCATCTCCGGTTTCATGGGTGACAACATGGTT 442 
Bo.ef.CDS          TACAACACCGATAAGGTTCCCTTCGTTGCCATCTCCGGTTTCATGGGTGACAACATGGTT 600 
                   ************************************************************ 
 
Bo.ef.partial      GAGCGCTCCACCAACATGCCATGGTACAAGGGCAAGACCTTGGTCGAGGCCCTCGACATG 502 
Bo.ef.CDS          GAGCGCTCCACCAACATGCCATGGTACAAGGGCAAGACCTTGGTCGAGGCCCTCGACATG 660 
                   ************************************************************ 
 
Bo.ef.partial      ATGGAGCCCCCAAAGAGGCCCGTTGACAAGCCACTTCGTCTTCCCATCCAGGGTGTCTAC 562 
Bo.ef.CDS          ATGGAGCCCCCAAAGAGGCCCGTTGACAAGCCACTTCGTCTTCCCATCCAGGGTGTCTAC 720 
                   ************************************************************ 
 
Bo.ef.partial      AAGATCGGTGGTATCGGTACCGTGCCCGTCGGTCGTGTCGAGACTGGTCAGCTCAAGGCT 622 
Bo.ef.CDS          AAGATCGGTGGTATCGGTACCGTGCCCGTCGGTCGTGTCGAGACTGGTCAGCTCAAGGCT 780 
                   ************************************************************ 
 
Bo.ef.partial      GGTATGGTCCTCACCTTCGCCCCCAACCCCATCACCACCGAGTGCAAATCTGTTGAAATG 682 
Bo.ef.CDS          GGTATGGTCCTCACCTTCGCCCCCAACCCCATCACCACCGAGTGCAAATCTGTTGAAATG 840 
                   ************************************************************ 
 
Bo.ef.partial      CACCACGAAGTCGTTGAGGTTGCCTACCCTGGTGACAACGTCGGTTTCAACGTAAAGAAC 742 
Bo.ef.CDS          CACCACGAAGTCGTTGAGGTTGCCTACCCTGGTGACAACGTCGGTTTCAACGTAAAGAAC 900 
                   ************************************************************ 
 
Bo.ef.partial      GTGTCTACCTCTGACATCCGCAGTGGTCACGTCGCCTCCGACTCCAAGAACGACCCCGCC 802 
Bo.ef.CDS          GTGTCTACCTCTGACATCCGCAGTGGTCACGTCGCCTCCGACTCCAAGAACGACCCCGCC 960 
                   ************************************************************ 
 
Bo.ef.partial      AAGGCCGCTGTGTCCTTCAGCGCCCAGGTCATTGTGCTTAACCACCCTGGTAACATCAAG 862 
Bo.ef.CDS          AAGGCCGCTGTGTCCTTCAGCGCCCAGGTCATTGTGCTTAACCACCCTGGTAACATCAAG 1020 
                   ************************************************************ 
 
Bo.ef.partial      GCTGGTTACACCCCCGTTGTTGACTGTCACACTGCCCACGTTTCCTGCAAGTTCGACGAG 922 
Bo.ef.CDS          GCTGGTTACACCCCCGTTGTTGACTGTCACACTGCCCACGTTTCCTGCAAGTTCGACGAG 1080 
                   ************************************************************ 
 
Bo.ef.partial      ATCACCTGCCGTATGGAC------------------------------------------ 940 
Bo.ef.CDS          ATCACCTGCCGTATGGACAAGCGTACTGGTAAATCCCTTGAGGAGAACCCCAAGAGCATC 1140 
                   ******************                                           
 
Bo.ef.partial      ------------------------------------------------------------ 940 
Bo.ef.CDS          AAGAATGGTGACGCCGCCATTGTCACCCTCAAGCCATGCAAGCCCATGGTCGTCGAATCC 1200 
                                                                                
 
Bo.ef.partial      ------------------------------------------------------------ 940 
Bo.ef.CDS          TTCACTGAGTACGCCCCTCTTGGTCGTTTCGCCGTTCGTGACATGAAGCAGACTGTTGCT 1260 
                                                                                
 
Bo.ef.partial      ------------------------------------------------------------ 940 
Bo.ef.CDS          GTCGGTGTCATCAAGAGCGTCGAGAAGAAGGAGCCTGGTTCATCTGCCAAGATCACCAAG 1320 
                                                                                
 
Bo.ef.partial      --------------------------- 940 
Bo.ef.CDS          TCCGCCCAGAAGGCCGCTAAGAAGTGA 1347 
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Appendix IV 
 
Appendix IV.1: Babesia ovis sequencing result of the amplicons obtained with primers pr-ef-ig1/ 
pr-ef-ovis-specific (332 base pairs). 
TTTTCTAGCTCTTGGTAGGNTGACCTACCAGCTGCTTGCGTCTGTCACTGGAAGTGGGGACACCCTGG
GGGTCTTCTGTCATTTGAAACCACATGTAACAGGCCCAGTAAAAAAAAGCACAAGAGTTATTTGATAC
CNGGGAAAACAAGAAGAAAGGGGTCCTTGCTTGGTACCCGAGGTTGTGTTTNTGATCAGAACCCCCAG
CTTGCCCGGGCTGTTTCAGTGCCACACGAACTTGGGAAGGAAACGGAGCAAGGGGAAAAGGAAACCTG
TAGACGAATGAAAAGGTATTCCATCTTCCTACAATCACGCCGGCCCAATGTAAGACNTCA  
Appendix IV.2. Babesiidae annotated sequence producing significant alignments with the B. ovis 
sequence obtained from amplification with primers PF-Ef-IG1 and PR-Ef-ovis-specific. 
 
Description 
Maximum 
Score 
Total 
Score 
Percent 
Query 
Coverage 
Expect 
Value 
Maximum 
Percent 
Identity 
GenBank 
Accession 
Number 
Babesia divergens 
genome assembly 
454hybrid_PBjelly, 
scaffold Contig0 
33.7 33.7 8% 1.0 86% LK934710.1 
Babesia bovis 
mRNA for e2f-
associated 
phosphoprotein, 
complete cds, clone: 
XBBk004120, strain: 
Texas 
31.9 31.9 5% 3.7 100%  AK440679.1 
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Appendix V 
Appendix V.1: Babesia ovis sequencing result of the amplicons obtained with primers PR-
Ef-IG3/ PR-Ef-ovis-specific (745 base pairs). 
ACGTGAACCGATTGTTTGGCACATATGCCATTCGTTCTTTGTTATAGGTGGGCGTGCTTGCGTGGAAC
ACTTTGACGTCTTTACACAACCTAGACCGTCACTTAAAATATGAATAGATATAGGTCCTTCACACTCC
CTGTATTTAGGTGGAGGTGTGCGCCGAGTTCGCGATGTTACAAACGGTTCTCTAGCAGTACCACTGCT
ACGCCAGAAGAATTGTCCCATTCTCCTAACCGGAAGGAGCAATTATTCTGGCAACTAAAGGTAGCATC
ATATGTATCTGGTATAGCCATATCTATCTACGGTACATATGTTTTTGTCAGCTCAGGTAAGGTCTACC
TATGAGTCTCCGTAAATGTGTGCAGGATTCCAGCTGGACAGATCCAAGCGAAAGGTTCTGTTACATTT
CTATGGCATGCTATATGGGAATACATTACCTAAACGCGTTCAAGCCTTACTGAATTCGCGATACAGTG
CTTGTTTAGATCAGGATGTGTTACGTTATCTCTCTGCATACTTTATTAAATTCGACTTGATAAAAGAC
AATGGGTTTACACGTTGAGACGCCGTTTTGTTTCTCGAAAATATCGGCATGGACGCCACCGATCCCTT
TGTGGCCCAGTTTATCGCAGCAGCAAGTGGTGATTCAATGGAACGCCGTATGGTCATCGGTTGCTCTC
TTCAGGAATTCGCTGAACTCATTGAGGCGCTTGTGTTAGAAGAGAAAATAAAGACAGCAAGTTAC 
 
Appendix V.2 Babesia ovis elongation factor 1α 5’ flanking region sequence retrieved from 
B. ovis Israeli strain draft genome (Bo_EFG 5'UTR placed at the end of the contig). 
GCGTGTCTTCGGTACATCAGTGGAGACGTCCACTGTGTGTATTCTGTTGTATAGTTGTGTATAATTGC
GCTGCAAATTTGTGTATTGTGCTTGGTGTAGCTTGTTCTGGCCATACTAACCACTCGCAGATTGGCCT
TTGCTAACGTTTAACCAAA 
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Appendix VI 
Appendix VI.1: Babesia ovis rhoptry protein gene and 3' end sequence obtained in the present 
study. 
TTGTCAACTGtCTTnGCATAACGACCCAATTAGTGCTAACATTCATGTACCACTTTTGTTTa
CCATGATTCTAAATATTGCGTTAATTATTTTCACAGCTCGTTCTATTTCAGTAGGATGCCTT
CAACCAACTATGGTAGTAACACTTGACAAAGCGCATTCGTTTTAACCTTTATAATTCGGGTA
ATATGACGTTATGCAATGAAAATATTAGTCTATCGACAATTGCTGATTGAATCCTACACATT
TCACTATTTATAAACGACGACATAACATATGCTGGTAGCCTTTTATATAAGTATATTACGTC
TAAAGCAATCCGTATAGGTTAACAAGACGCAATAGAGGTAAGCAACGTTCTGAGTTCGGTTA
TTGTTAGTATTTTTTATAAAATAACAAAGAAATTATTTGTTACGTTGGAACCATAGTTGAGC
GATAACAATGTAGCCACATGGTTGTATTCGTCAACAATGCAATGGAGCTCGTTCtTTTTTTT
ATTAAAGAATAAATGGATAACGGCGATACATTCCTTGTGGTGGCTACATTTTCAAAGGTGGA
AGATAACCAATATCAGACACCGATACACCATTTCCTATAGGTGGCTTAATCATTACATTGTC
TTCTGTCGTTTGTATTTTTAGACAAACATTTCACCGACAGTGTTACCTCCGTCATGATTCTC
CATGTCAACGGTTTCGGTAGCTACATCGGCTACACTATCGTTATTCATCCTTTGGGGTGAGC
TAATGTAGCGCCAATTTACAGGGCGCTTGTGTCCCAAGTTCTCAAATGATTCTTTAATGGGG
GCACCAATCTTGTTCTCAAAGAAGTCCTTGGTAGGAGCACCTATCTTGTTCTCGAAGAAGTC
CTTGGTGCGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTA
CCAAGCTTGATGCATAGCTTGAG 
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Appendix VII 
Appendix VII.1: Alignment between the clone3a sequence and the expected pBbovis sequence. 
 
Clone 3a      -----------------------------------------------------------t 1 
Expected      caccacacccgccgcgcttaatgcgccgctacagggcgcgtcccattcgccattcaggct 480 
                                                                         * 
 
Clone 3a      gcGCaActGTTGGGaAgGGCgAtCGGTGCnGGCCntTttcgctaTTACgccAgcTGGCGa 61 
Expected      gcgcaactgttgggaagggcgatcggtgc-gggcctcttcgctattacgccagctggcga 539 
              ***************************** ** * * *********************** 
 
Clone 3a      AAngGGGATgTGCTGCAAGGCGATTAAGTTGGGTAACgncaGGGttTTcCCAGTCACGAC 121 
Expected      aagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgac 599 
              ** *********************************** ********************* 
 
Clone 3a      GTTGTAAAACGACngGcCAGTGAATTGTAATACGACTCACTATAGGGCGAATTgGGTACC 181 
Expected      gttgtaaaacgac-ggccagtgaattgtaatacgactcactatagggcgaattgggtacc 658 
              ************* ********************************************** 
 
Clone 3a      GGGccCCCcCTCGAGGTcgACGGTATCGATAAGCTTCACGTAATAAATGAGATAAATAAG 241 
Expected      gggccccccctcgaggtcgacggtatcgatAAGCTTcacgtaataaatgagataaataag 718 
              ************************************************************ 
 
Clone 3a      TATATGTCATGTATAAATTTGGGGTATAAntTTAATTGTAGAAGGTGGAGATAGTACGGT 301 
Expected      tatatgtcatgtataaatttggggtataattttaattgtagaaggtggagatagtacggt 778 
              ***************************** ****************************** 
 
Clone 3a      AAAAACTGAGATGATATATAATATATGATGAATATATAAACTTGACAGGTCAAGATTACT 361 
Expected      aaaaactgagatgatatataatatatgatgaatatataaacttgacaggtcaagattact 838 
              ************************************************************ 
 
Clone 3a      TGATCAGATTTAATTAGTTGTGATAAAGCGGAAATTCCCATATATGTCATCCCGTTAAAG 421 
Expected      tggtcagatttaattagttgtgataaagcggaaattcccatatatgtcatcccgttaaag 898 
              ** ********************************************************* 
 
Clone 3a      GTATTAATAGCATTTTAAGAATATATTTCACAAATATGATATACCATACATCTGATAGAA 481 
Expected      gtattaatagcattttaagaatatatttcacaaatatgatataccatacatctgatagaa 958 
              ************************************************************ 
 
Clone 3a      TTATGCATCGATATTCGTCGTTATAGGCTTAGTTGCGCACAACGAAAAGGTATGTGTATA 541 
Expected      ttatgcatcgatattcgtcgttataggcttagttgcgcacaacgaaaaggtatgtgtata 1018 
              ************************************************************ 
 
Clone 3a      TACTTAATTATATTTCAATCAAACGATGGGTGACAAATGTGTGGCGTGGAGCAAAGCAAA 601 
Expected      tacttaatgatatttcaatcaaacgatgggtgacaaatgtgtggcgtggagcaaagcaaa 1078 
              ******** *************************************************** 
 
Clone 3a      ACAGCACCACAACCTTTACAAAGGGATCTTCATTAGTCCTTTGCAGTGTCTTTATAACTT 661 
Expected      acagcaccacaacctttacaaagggatcttcattagtcctttgcagtgtctttataactt 1138 
              ************************************************************ 
 
Clone 3a      AATAAAGTAATTCCACGCAAGAATAGTGATTATATCGCCAACAACGCACTTTTGTGATGT 721 
Expected      aataaagtaattccacgcaagaatagtgattatatcgccaacaacgcacttttgtgatgt 1198 
              ************************************************************ 
 
Clone 3a      AAGTCAGGCCCCTGTCATTTTGCTTTGTGGGTGGTGTTATTTCATGAAGCAGGCGACTAC 781 
Expected      aagtcaggcccctgtcattttgctttgtgggtggtgttatttcatgaagcaggcgactac 1258 
              ************************************************************ 
 
Clone 3a      TTCTTGTCGAGCTGCTGTGTGTATATTCTACTTTTGAGGCTATTATATACACTGATGTGT 841 
Expected      ttcttgtcgagctgctgtgtgtatatcctacttttgaggctattatatacactgatgtgt 1318 
              ************************** ********************************* 
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Clone 3a      TTAGACATTTGTGTTATTTAATGCTTGATTTAACGTTTTTTCAATTGTGTTTGCCGATAC 901 
Expected      ttggacatttgtgttatttaatgcttgatttaacgttttttcaattgtgtttgccgacac 1378 
              ** ****************************************************** ** 
 
Clone 3a      TAATGTTGTCTCAGAGATAATTTATTGCAACTTTACGAAAAAGCTTGATATCATGGAAGA 961 
Expected      taatgttgtctcagagataatttattgcaactttacgaaaAAGCTTGATATCatggaaga 1438 
              ************************************************************ 
 
Clone 3a      CGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTAGAGGATGGAACCGCTGG 1021 
Expected      cgccaaaaacataaagaaaggcccggcgccattctatccgctggaagatggaaccgctgg 1498 
              ****************************************** ** ************** 
 
Clone 3a      AGAGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTAC 1081 
Expected      agagcaactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttac 1558 
              ************************************************************ 
 
Clone 3a      AGATGCACATATCGAgGtgAACaTCACGTACGCGGaAtantnG----------------- 1124 
Expected      agatgcacatatcgaggtggacatcacttacgctgagtacttcgaaatgtccgttcggtt 1618 
              ******************* ******* ***** ** ** *                    
 
Clone 3a      --------------------------tCTgaTgagnTgCGTTtATAaTGGCACAAaCTCA 34 
Expected      agggcggaaagatcgccgtgtaaAGATCTgatgagatgcgtttataatggcacaaactca 3120 
                                        ********* ************************ 
 
Clone 3a      ACAAATGATGTATCGTCATCTGATCCATCGGTTTTCAATATTGTATTGGATGCAATATCT 94 
Expected      acaaatgatgtatcgtcatctgatccatcggttttcaatattgtattggatgcaatatct 3180 
              ************************************************************ 
 
Clone 3a      GAATGCATATGATGCGACAGTTTCCATCATCGGGTGCCGAATCGTAACTCTCATAACACC 154 
Expected      gaatgcatatgatgcgacagtttccatcatcgggtgccgaatcgtaactctcataacacc 3240 
              ************************************************************ 
 
Clone 3a      ATTTTAAGTTATGTAAACTAGTATCTATGTTTATGGTTTACGTAAAATGAATGTTTGAGT 214 
Expected      attttaagttatgtaaactagtatctatgtttatggtttacgtaaaatgaatgtttgagt 3300 
              ************************************************************ 
 
Clone 3a      CTACAGGAAGGAACACGTGTCTAGAAGTATTTATTTCGTGAATGTACGTCATATATTTTT 274 
Expected      ctacaggaaggaacacgtgtctagaagtatttatttcgtgaatgtacgtcatatattttt 3360 
              ************************************************************ 
 
Clone 3a      ATGTATACGTGAACCTCACTAAAGGAAATTTTTGATGTTTTACGTATGCATTTATTAAAC 334 
Expected      atgtatacgtgaacctcactaaaggaaatttttgatgttttacgtatgcatttattaaac 3420 
              ************************************************************ 
 
Clone 3a      AATACTCTGTTAAATTATTCCATACGCTAAGATATGATTCCTTTCTCGCAAATCTCGGTT 394 
Expected      aatactctgttaaattattccatacgctaagatatgattcctttctcgcaaatctcggtt 3480 
              ************************************************************ 
 
Clone 3a      ATTTTATAACAATAAAGTATACAAATAAGCATAATATTCCCATGAAGTGATCTATAATGC 454 
Expected      attttataacaataaagtatacaaataagcataatattcccatgaagtgatctataatgc 3540 
              ************************************************************ 
 
Clone 3a      AGTTATATTCtCATCAATAAtAAAACancAAATTAAACGTATTTGTTATAAAAATGAAAC 514 
Expected      agttatattctcatcaataataaaacaacaaattaaacgtatttgttataaaaatgaaac 3600 
              *************************** ******************************** 
 
Clone 3a      ATAACATATATGATGTTCATTCAAGATGTATTATATATATATAT--ATACAAACATCtTT 572 
Expected      ataacatatatgatgttcattcaagatgtattatatatatatatatacacaaacatcttt 3660 
              ********************************************  * ************ 
 
Clone 3a      TTTTAAAAATTATTTGCTTATAAATGTAAACATATCATGCAATTGTGCACAAACACATCG 632 
Expected      ttttaaaaattatttgcttataaatgtaaacatatcatgcaattgtgcacaaacacatcg 3720 
              ************************************************************ 
 
Clone 3a      CATGATTATGAAGAATTAAAATTAACATTACACAATGAAATTTTATATTAAGTGGACGAA 692 
Expected      catgattatgaagaattaaaattaacattacacaatgaaattttatattaagtggacgaa 3780 
              ************************************************************ 
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Clone 3a      TTAGGTTTATGTTTACATATAAGGTGGTGATATGTTTGGTCTTATGATGTTGTTATACAC 752 
Expected      ttaggtttatgtttacatataaggtggtgatatgtttggtcttatgatgttgttatacac 3840 
              ************************************************************ 
 
Clone 3a      ATTCATGGCACGACATTTTGATAGTTTAGTAATGAAGTCTAGTTAATGTTGCCAATGCTA 812 
Expected      attcatggcacgacattttgatagtttagtaatgaagtctagttaatgttgccaatgcta 3900 
              ************************************************************ 
 
 Clone 3a     GCCAATTAAAATAGGCTAAATTATATTTTTATGAATAATTTCTTTTTTTtCCAATCCACG 872 
Expected      gccaattaaaataggctaaattatatttttatgaataatttcttttttttccaatccacg 3960 
              ************************************************************ 
 
Clone 3a      ATGGCAGACTTGGCAACAGCAATTGCTGAATTTGATTCTCTTAACGAATTTTCAAAACCT 932 
Expected      atggcagacttggcaacagcaattgctgaatttgattctcttaacgaattttcaaaacct 4020 
              ************************************************************ 
 
Clone 3a      GATGCTAAATTATTATCCACAATACTACTATCGGATGGCGTAAAATTATCACAACAACTT 992 
Expected      gatgctaaattattatccacaatactactatcggatggcgtaaaattatcacaacaactt 4080 
              ************************************************************ 
 
Clone 3a      AAGGCGCTTTACTTCTGTCGTGATTTATCTTCTAGTGAATGTGCTACTATCCTTAAAAAG 1052 
Expected      aaggcgctttacttctgtcgtgatttatcttctagtgaatgtgctactatccttaaaaag 4140 
              ************************************************************ 
 
Clone 3a      GCACTTGAAGTACACTACGATACATTCTTGAGGTAGGTAATAGCACGTAATGTTATTATG 1112 
Expected      gcacttgaagtacactacgatacattcttgaggtaggtaatagcacgtaatgttattatg 4200 
              ************************************************************ 
 
Clone 3a      TTACCTTATTCATTCTTCATCTTCTTATAGACATGAAATTGCTTATGTAATTGGACAAGC 1172 
Expected      ttaccttattcattcttcatcttcttatagacatgaaattgcttatgtaattggacaagc 4260 
              ************************************************************ 
 
Clone 3a      AGAATGCGAGGAAGCAGCTGACGTATTGGTTCGCCTTTTGGAGGATACTAATGAAGACCC 1232 
Expected      agaatgcgaggaagcagctgacgtattggttcgccttttggaggatactaatgaagaccc 4320 
              ************************************************************ 
 
Clone 3a      TATGGTCAGACATGAGGTATGTCGTTTAACTCTTTGACATATCGTTCGTAGGGGATCCAC 1292 
Expected      tatggtcagacatgaggtatgtcgtttaactctttgacatatcgttcgtaggggatccac 4380 
              ************************************************************ 
 
Clone 3a      TAGTTCTAGAGCGGCCGCCACCGCGgtggAGCTCCAGCTTTTgttCCCttTAg------- 1345 
Expected      tagttctagagcggccgccaccgcggtggagctccagcttttgttccctttagtgagggt 4440 
              *****************************************************        
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Appendix VIII 
Appendix VIII.1: Alignment between the clone9 sequence and pBbovis-luc sequence.  
 
 
Clone9          -----CatgTATAAATTTGgGGTATAATTTTAATTGTAGAAGGTGGAGATAGTangGTAA 55 
pbovis-luc      tatgtcatgtataaatttggggtataattttaattgtagaaggtggagatagtacggtaa 780 
                     ************************************************* ***** 
 
Clone9          AAantGAGATGATATATAATATATGATGAATATATAAACTTGACAGGTCAAGATTACTTG 115 
pbovis-luc      aaactgagatgatatataatatatgatgaatatataaacttgacaggtcaagattacttg 840 
                *** ******************************************************** 
 
Clone9          ATCAGATTTAATTAGTTGTGATAAAGCGGAAATTCCCATATATGTCATCCCGTTAAAGGT 175 
pbovis-luc      gtcagatttaattagttgtgataaagcggaaattcccatatatgtcatcccgttaaaggt 900 
                 *********************************************************** 
 
Clone9          ATTAATAGCATTTTAAGAATATATTTCACAAATATGATATACCATACATCTGATAGAATT 235 
pbovis-luc      attaatagcattttaagaatatatttcacaaatatgatataccatacatctgatagaatt 960 
                ************************************************************ 
 
Clone9          ATGCATCGATATTCGTCGTTATAGGCTTAGTTGCGCACAACGAAAAGGTATGTGTATATA 295 
pbovis-luc      atgcatcgatattcgtcgttataggcttagttgcgcacaacgaaaaggtatgtgtatata 1020 
                ************************************************************ 
 
Clone9          CTTAATTATATTTCAATCAAACGATGGGTGACAAATGTGTGGCGTGGAGCAAAGCAAAAC 355 
pbovis-luc      cttaatgatatttcaatcaaacgatgggtgacaaatgtgtggcgtggagcaaagcaaaac 1080 
                ****** ***************************************************** 
 
Clone9          AGCACCACAACCTTTACAAAGGGATCTTCATTAGTCCTTTGCAGTGTCTTTATAACTTAA 415 
pbovis-luc      agcaccacaacctttacaaagggatcttcattagtcctttgcagtgtctttataacttaa 1140 
                ************************************************************ 
 
Clone9          TAAAGTAATTCCACGCAAGAATAGTGATTATATCGCCAACAACGCACTTTTGTGATGTAA 475 
pbovis-luc      taaagtaattccacgcaagaatagtgattatatcgccaacaacgcacttttgtgatgtaa 1200 
                ************************************************************ 
 
Clone9          GTCAGGCCCCTGTCATTTTGCTTTGTGGGTGGTGTTATTTCATGAAGCAGGCGACTACTT 535 
pbovis-luc      gtcaggcccctgtcattttgctttgtgggtggtgttatttcatgaagcaggcgactactt 1260 
                ************************************************************ 
 
Clone9          CTTGTCGAGCTGCTGTGTGTATATTCTACTTTTGAGGCTATTATATACACTGATGTGTTT 595 
pbovis-luc      cttgtcgagctgctgtgtgtatatcctacttttgaggctattatatacactgatgtgttt 1320 
                ************************ *********************************** 
 
Clone9          AGACATTTGTGTTATTTAATGCTTGATTTAACGTTTTTTCAATTGTGTTTGCCGATACTA 655 
pbovis-luc      ggacatttgtgttatttaatgcttgatttaacgttttttcaattgtgtttgccgacacta 1380 
                 ****************************************************** **** 
 
Clone9          ATGTTGTCTCAGAGATAATTTATTGCAACTTTACGAAAAAGCTTGATATCATGGAAGACG 715 
pbovis-luc      atgttgtctcagagataatttattgcaactttacgaaaAAGCTTGATATCatggaagacg 1440 
                ************************************************************ 
 
Clone9          CCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTAGAGGATGGAACCGCTGGAG 775 
pbovis-luc      ccaaaaacataaagaaaggcccggcgccattctatcctcttgaggatggaaccgctggag 1500 
                ************************************* ** ******************* 
 
Clone9          AGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTACAG 835 
pbovis-luc      agcaactgcataaggctatgaagagatacgccctggttcctggaacaattgcttttacag 1560 
                ************************************************************ 
 
Clone9          ATGCAC------------------------------------------------------ 841 
pbovis-luc      atgcacatatcgaggtgaacatcacgtacgcggaatacttcgaaatgtccgttcggttgg 1620 
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Clone9          -------------------------------------------cGTGgattncGTCGCCA 17 
pbovis-luc      ttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtggattacgtcgcca 2940 
                                                           ******** ******** 
 
Clone9          GTCAAGTaacaACCGCGAAAAAGTTGCGCGGAGGAGTTGTGTTTGTGGACGAAGTACCGA 77 
pbovis-luc      gtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacgaagtaccga 3000 
                ************************************************************ 
 
Clone9          AAGGTCTTACCGGAAAACTCGACGCAAGAAAAATCAGAGAGATCCTCATAAAGGCCAAGA 137 
pbovis-luc      aaggtcttaccggaaaactcgacgcaagaaaaatcagagagatcctcataaaggccaaga 3060 
                ************************************************************ 
 
Clone9          AGGGCGGAAAGTCCAAATTGTAAAGATCTGATGAGATGCGTTTATAATGGCACAAACTCA 197 
pbovis-luc      agggcggaaagtccaaattgtaaAGATCTgatgagatgcgtttataatggcacaaactca 3120 
                ************************************************************ 
 
Clone9          ACAAATGATGTATCGTCATCTGATCCATCGGTTTTCAATATTGTATTGGATGCAATATCT 257 
pbovis-luc      acaaatgatgtatcgtcatctgatccatcggttttcaatattgtattggatgcaatatct 3180 
                ************************************************************ 
 
Clone9          GAATGCATATGATGCGACAGTTTCCATCATCGGGTGCCGAATCGTAACTCTCATAACACC 317 
pbovis-luc      gaatgcatatgatgcgacagtttccatcatcgggtgccgaatcgtaactctcataacacc 3240 
                ************************************************************ 
 
Clone9          ATTTTAAGTTATGTAAACTAGTATCTATGTTTATGGTTTACGTAAAATGAATGTTTGAGT 377 
pbovis-luc      attttaagttatgtaaactagtatctatgtttatggtttacgtaaaatgaatgtttgagt 3300 
                ************************************************************ 
 
Clone9          CTACAGGAAGGAACACGTGTCTAGAAGTATTTATTTCGTGAATGTACGTCATATATTTTT 437 
pbovis-luc      ctacaggaaggaacacgtgtctagaagtatttatttcgtgaatgtacgtcatatattttt 3360 
                ************************************************************ 
 
Clone9          ATGTATACGTGAACCTCACTAAAGGAAATTTTTGATGTTTTACGTATGCATTTATTAAAC 497 
pbovis-luc      atgtatacgtgaacctcactaaaggaaatttttgatgttttacgtatgcatttattaaac 3420 
                ************************************************************ 
 
Clone9          AATACTCTGTTAAATTATTCCATACGCTAAGATATGATTCCTTTCTCGCAAATCTCGGTT 557 
pbovis-luc      aatactctgttaaattattccatacgctaagatatgattcctttctcgcaaatctcggtt 3480 
                ************************************************************ 
 
Clone9          ATTTTATAACAATAAAGTATACAAATAAGCATAATATTCCCATGAAGTGATCTATAATGC 617 
pbovis-luc      attttataacaataaagtatacaaataagcataatattcccatgaagtgatctataatgc 3540 
                ************************************************************ 
 
Clone9          AGTTATATTCTCATCAATAATAAAACAACAAATTAAACGTATTTGTTATAAAAATGAAAC 677 
pbovis-luc      agttatattctcatcaataataaaacaacaaattaaacgtatttgttataaaaatgaaac 3600 
                ************************************************************ 
 
Clone9          ATAACATATATGATGTTCATTCAAGATGTATTATATATATATAT--ATACAAACATCTTT 735 
pbovis-luc      ataacatatatgatgttcattcaagatgtattatatatatatatatacacaaacatcttt 3660 
                ********************************************  * ************ 
 
Clone9          TTTTAAAAATTATTTGCTTATAAATGTAAACATATCATGCAATTGTGCACAAACACATCG 795 
pbovis-luc      ttttaaaaattatttgcttataaatgtaaacatatcatgcaattgtgcacaaacacatcg 3720 
                ************************************************************ 
 
Clone9          CATGATTATGAAGAATTAAAATTAACATTACACAATGAAATTTTATATTAAGTGGACGAA 855 
pbovis-luc      catgattatgaagaattaaaattaacattacacaatgaaattttatattaagtggacgaa 3780 
                ************************************************************ 
 
Clone9          TTAGGTTTATGTTTACATATAAGGTGGTGATATGTTTGGTCTTATGATGTTGTTATACAC 915 
pbovis-luc      ttaggtttatgtttacatataaggtggtgatatgtttggtcttatgatgttgttatacac 3840 
                ************************************************************ 
 
Clone9          ATTCATGGCACGACATTTTGATAGTTTAGTAATGAAGTCTAGTTAATGTTGCCAATGCTA 975 
pbovis-luc      attcatggcacgacattttgatagtttagtaatgaagtctagttaatgttgccaatgcta 3900 
                ************************************************************ 
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Clone9          GCCAATTAAAATAGGCTAAATTATATTTTTATGAATAATTTCTTTTTTTtCCAATCCACG 1035 
pbovis-luc      gccaattaaaataggctaaattatatttttatgaataatttcttttttttccaatccacg 3960 
                ************************************************************ 
 
Clone9          ATGGCAGACTTGGCAACAGCAATTGCTGAATTTGATTCTCTTAACGAATTTTCAAAACCT 1095 
pbovis-luc      atggcagacttggcaacagcaattgctgaatttgattctcttaacgaattttcaaaacct 4020 
                ************************************************************ 
 
Clone9          GATGCTAAATTATTATCCACAATACTACTATCGGATGGCGTAAAATTATCACAACAACTT 1155 
pbovis-luc      gatgctaaattattatccacaatactactatcggatggcgtaaaattatcacaacaactt 4080 
                ************************************************************ 
 
Clone9          AAGGCGCTTTACTTCTGTCGTGATTTATCTTCTAGTGAATGTGCTACTATCCTTAAAAAG 1215 
pbovis-luc      aaggcgctttacttctgtcgtgatttatcttctagtgaatgtgctactatccttaaaaag 4140 
                ************************************************************ 
 
Clone9          GCACTTGAAGTACACTACGATACATTCTTGAGGTAGGTAATAGCACGTAATGTTATTATG 1275 
pbovis-luc      gcacttgaagtacactacgatacattcttgaggtaggtaatagcacgtaatgttattatg 4200 
                ************************************************************ 
 
Clone9          TTACCTTATTCATTCTTCATCTTCTTATAGACATGAAATTGCTTATGTAATTGGACAAGC 1335 
pbovis-luc      ttaccttattcattcttcatcttcttatagacatgaaattgcttatgtaattggacaagc 4260 
                ************************************************************ 
 
Clone9          AGAATGCGAGGAAGCAGCTGACGTATTGGTTCGCCTTTTGGAGGATACTAATGAAGACCC 1395 
pbovis-luc      agaatgcgaggaagcagctgacgtattggttcgccttttggaggatactaatgaagaccc 4320 
                ************************************************************ 
 
Clone9          TATGGTCAGACATGAGGTATGTCGTTTAACTCTTTGACATATCGTTCGTAGGGGATCCAC 1455 
pbovis-luc      tatggtcagacatgaggtatgtcgtttaactctttgacatatcgttcgtaggggatccac 4380 
                ************************************************************ 
 
Clone9          TAGTTCTAGAGCGGCCGCCACCGCGgtggAGCTCCAGCTTTTgttCCCttTAg------- 1508 
pbovis-luc      tagttctagagcggccgccaccgcggtggagctccagcttttgttccctttagtgagggt 4440 
                *****************************************************     
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Appendix VIII.1: Alignment between the clone3 sequence and pBovata-luc sequence.  
 
clone3          -----------------GCCGGGATGTATACGACTCACTATAGGGCGAATTGGGTACCGG 43 
povata-luc      TTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCGG 660 
                                 *         ********************************* 
 
clone3          GCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTCACTCATTTAGATTGCGACATGTTAC 103 
povata-luc      GCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTCACTCATTTAGATTGCGACATGTTAC 720 
                ************************************************************ 
 
clone3          AAGTAATGTGGCGTTCAGTATGCTTTCTGGGATGCCTAAAAGACGATGTGCGGCACGCCT 163 
povata-luc      AAGTAATGTGGCGTTCAGTATGCTTTCTGGGATGCCTAAAAGACGATGTGCGGCACGCCT 780 
                ************************************************************ 
 
clone3          CAGCGTAATCCCACGTTAGACATACAAACGTTGTGATGAAGTTGCAATGTTAGTTATGTG 223 
povata-luc      CAGCGTAATCCCACGTTAGACATACAAACGTTGTGATGAAGTTGCAATGTTAGTTATGTG 840 
                ************************************************************ 
 
clone3          TATTAAGCGTATATAAGTAACTTCGAGTTATCACAGCATTCTGCCGCGAAATTGCTCGCG 283 
povata-luc      TATTAAGCGTATATAAGTAACTTCGAGTTATCACAGCATTCTGCCGCGAAATTGCTCGCG 900 
                ************************************************************ 
 
clone3          GAATGTGATTGGCGTGTCACGAAAAATTTTACCACAACATTGCCGGCTATTATATGCACA 343 
povata-luc      GAATGTGATTGGCGTGTCACGAAAAATTTTACCACAACATTGCCGGCTATTATATGCACA 960 
                ************************************************************ 
 
clone3          GAACGTTCATACACTTTTGTGTAAAGCGATGCATCATAAGTAAAAGTGTGTGGTCTTGCT 403 
povata-luc      GAACGTTCATACACTTTTGTGTAAAGCGATGCATCATAAGTAAAAGTGTGTGGTCTTGCT 1020 
                ************************************************************ 
 
clone3          GTGCCTGTTCGGTGAACGGCGCGTGAGATGGTCTAATGCGATAATATAATACTGCTTTTA 463 
povata-luc      GTGCCTGTTCGGTGAACGGCGCGTGAGATGGTCTAATGCGATAATATAATACTGCTTTTA 1080 
                ************************************************************ 
 
clone3          CACATTAAACAAATGACAATGGTACTGCTAAAAAAGGTGTTCAATGAACATCCTGAAGAG 523 
povata-luc      CACATTAAACAAATGACAATGGTACTGCTAAAAAAGGTGTTCAATGAACATCCTGAAGAG 1140 
                ************************************************************ 
 
clone3          TAATTCGGTTTCATCCGCTGTTACCACTATATACCGGTTTACGGCGATATTACCCCACTG 583 
povata-luc      TAATTCGGTTTCATCCGCTGTTACCACTATATACCGGTTTACGGCGATATTACCCCACTG 1200 
                ************************************************************ 
 
clone3          CATCCTCACGCCGTATATTGAACGGAAATAAGTCACTACCATTCACTCGCGCTCTGCCGG 643 
povata-luc      CATCCTCACGCCGTATATTGAACGGAAATAAGTCACTACCATTCACTCGCGCTCTGCCGG 1260 
                ************************************************************ 
 
clone3          TACCAGTTTTATAAAACGCAGGTACAATCTAATTGATTTATATTGTAAGTTTCGTAGCAT 703 
povata-luc      TACCAGTTTTATAAAACGCAGGTACAATCTAATTGATTTATATTGTAAGTTTCGTAGCAT 1320 
                ************************************************************ 
 
clone3          CGCCGTTTTGTGTTACGTGTGGGTGTGATGGTTTAGACGGCGCGTCCGTGGACGGCCGTT 763 
povata-luc      CGCCGTTTTGTGTTACGTGTGGGTGTGATGGTTTAGACGGCGCGTCCGTGGACGGCCGTT 1380 
                ************************************************************ 
 
clone3          TTGCGTGTGTATGGTAGGCCACGGTTTCGCAACGATGCTGCGTCGCCTTGGTTGGTGATT 823 
povata-luc      TTGCGTGTGTATGGTAGGCCACGGTTTCGCAACGATGCTGCGTCGCCTTGGTTGGTGATT 1440 
                ************************************************************ 
 
clone3          CGTGGTGTATGGGCCATTTTGTGGTATTGTCGTGCGTCACACTCCATTAGACCCGTAGCT 883 
povata-luc      CGTGGTGTATGGGCCATTTTGTGGTATTGTCGTGCGTCACACTCCATTAGACCCGTAGCT 1500 
                ************************************************************ 
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clone3          AACTGTGCGCAGGTTTGCTATCGTTAAACCTTAAACAAGAAGCTTGATATCATGGAAGAC 943 
povata-luc      AACTGTGCGCAGGTTTGCTATCGTTAAACCTTAAACAAGAAGCTTGATATCATGGAAGAC 1560 
                ************************************************************ 
 
clone3          GCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTAGAGGATGGAACCGCTGGA 1003 
povata-luc      GCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCTCTTGAGGATGGAACCGCTGGA 1620 
                ************************************** ** ****************** 
 
clone3          GAGCAACTGCATAAGGCTATGAAGAGATACCCCCTGGTTCCTGGAACAATTGCTTTTACA 1063 
povata-luc      GAGCAACTGCATAAGGCTATGAAGAGATACGCCCTGGTTCCTGGAACAATTGCTTTTACA 1680 
                ****************************** ***************************** 
 
clone3          GATGCACATATCGAGGTGAAC--------------------------------------- 1084 
povata-luc      GATGCACATATCGAGGTGAACATCACGTACGCGGAATACTTCGAAATGTCCGTTCGGTTG 1740 
                *********************                                        
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Appendix X 
Appendix X.1: Representative pictures of Babesia ovis with and without blasticidin-S at 72h. Black 
arrows indicate B. ovis with a regular phenotype. Intraerythrocytic parasites were observed under a 
400x original magnification of a Motic BA210 LED trinocular compound microscope.  
 
 
